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Abrrevation 
AGM aorta-gonad-mesonephros 
AML acute myeloid leukemia 
APC allophycocyanin 
BasoE basophilic erythroblast 
BFU-E burst forming unit-erythroid 
BrdU bromdesoxyuridin  
CFU-E colony forming unit-erythroid 
CLP common lymphoid progenitor 
DNMT DNA methyltransferase 
EMT epithelia-mesenchymal transition 
ETP-ALL early T-cell precursor leukemia 
FITC fluorescein isothiocyanate 
G-CSF granulocyte colony-stimulating factor 
GO gene ontology 
GMP granulocyte-macrophage progenitor 
Hb hemoglobin 
HCT hematocrit 
HSC hematopoietic stem cell 
IHRES internal ribosome entry site 
IL interleukin 
iPS induced pluripotent stem cell 
JAK janus kinase 
KO knockout 
LKS 
lineage negative, c-Kit positive, Sca-1 positive 
population 
LMPP lymphoid-primed multipotent progenitor 
LT-HSC long-term hematopoietic stem cell 
MCV mean corpuscular volume 
MEP megakaryocyte-erythroid progenitor 
MDS myelodysplastic syndrome 
MPN myeloproliferative neoplasm 
MPP multipotent progenitor cell 
MWS Mowat-Wilson syndrome 
NuRD 
nucleosome remodeling and histone 
deacetylation 
OrthoE orthochromatic erythroblast 
PE phycoerthrin 
PerCP peridinin chlorophyll protein 
PFA paraformaldehyde 
PHZ phenylhydrayine 
PolyE polychromatic erythroblast 
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Poly I:C polyinosinic:polycytidylic acid 
PRC2 polycomb repressor complex 2 
ProE proerythroblast 
RBC red blood cell 
RIPA radio-immunoprecipitation assay 
RT room temperature 
TO thiazole orange 
qRT-PCR 
quantitative real time polymerase chain 
reaction 
RRBS reduced representation bisulfite sequencing 
ST-HSC short-term hematopoietic stem cell 
STAT signal transducer and activator of transcription 
UTR untranslated region 
WT wild type 
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1. Introduction 
1.1 Hematopoiesis 
1.1.1 Sites of hematopoiesis 
Hematopoiesis is the formation and developmental process of all types of 
peripheral blood and bone marrow cells. The primary sites of hematopoiesis 
change during the development of vertebrates. In various mammal species, it 
first takes place in the embryonic yolk sac blood islands. At later stages of 
development it moves to the aorta-gonad-mesonephros (AGM) region, 
placenta, fetal liver, spleen, and finally to the bone marrow, which then remains 
the major hematopoietic organ (Dzierzak and Speck, 2008).  
In an adult organism, bone marrow is the main location of hematopoietic cell 
production. However, in case of hematopoietic stress or medullary insufficiency, 
hematopoiesis will relocate to other organs, like liver or spleen. This is called 
extramedullary hematopoiesis (Munker and Munker, 2006).    
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Figure 1.1 Timeline of embryonic mouse and human hematopoietic development (Rieger 
and Schroeder, 2012). The primitive wave takes place in the yolk sac to generate primitive 
erythroid cells, and rapidly replaced by second wave, which also occurs in yolk sac but 
produce definitive erythroid/ myeloid progenitors. The third wave emerges first functional 
HSC generation in AGM region. Those HSCs soon home to and expand in the fetal liver 
and eventually seed the bone marrow. dpc, days after conception; wpc, weeks after 
conception.  
 
1.1.2 Hematopoietic stem cells 
Hematopoiesis is maintained by a small population of hematopoietic stem cells 
(HSCs), which are capable of self-renewal and giving rise to all hematopoietic 
lineages. As shown in Fig. 1.1 long-term hematopoietic stem cells (LT-HSCs) 
can replenish themselves by one of the daughter cell by asymmetric division, 
and the other daughter cell will differentiate into short-term hematopoietic stem 
cells (ST-HSCs), which are also multipotent, but only retain self-renewal 
capacity for a limited time ( ≈8 weeks) (Morrison and Weissman, 1994). 
ST-HSCs then differentiate into multipotent progenitor cells (MPPs), which in 
turn generate oligopotent megakaryocyte-erythroid progenitors (MEPs), 
granulocyte-macrophage progenitors (GMPs), and common lymphoid 
progenitors (CLPs). Those progenitor cells are responsible for erythropoiesis 
and megakaryocytopoiesis, myelopoiesis, and lymphopythoiesis respectively, 
and finally can give rise to functionally mature cells, including erythrocytes (red 
blood cells), thrombocytes (platelets), monocytes, granulocytes, B- and T- 
lymphocytes, etc. Each progenitor and mature blood cell type can be 
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distinguished by their surface antigen expression on the cell surface by the so 
called immunophenotype (Kiel et al., 2005; Passegue et al., 2003).   
 
 
Figure 1.2 Overview of hematopoietic differentiation hierarchy (Orkin and Zon, 2008) HSC: 
hematopoietic stem cell, CLP: common lymphoid progenitor, CMP: common myeloid 
progenitor, MEP: Megakaryocyte-erythrocyte progenitor, GMP: granulocyte-macrophage 
progenitor 
 
1.1.3 Transcription factors in hematopoietic development and 
lineage choice 
To continuously generate an suitable amount of functional blood cells, HSCs 
have to undergo cell-fate decisions to turn from quiescent state to proliferation, 
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self-renewal and differentiation. This processes are regulated by both extrinsic 
and intrinsic factors. As an important element of intrinsic regulatory network, 
many lineage specific nuclear regulators have been identified to govern HSC 
behavior (Fig. 1.1) (Orkin, 1995; Orkin and Zon, 2008; Zhu and Emerson, 
2002).  
The essential role of stem cell leukemia (SCL), also known as Tal1 in 
hematopoiesis was originally revealed by chromosomal translocation studies 
associated with T cell acute lymphoblastic leukemia coincidently (Begley et al., 
1989). SCL deletion in mice is lethal due to incapabillity of generating erythroid 
cells in the yolk sac, and SCL-/- embryonic stem cells cannot give rise to all 
myeloid and lymphoid cells (Porcher et al., 1996; Shivdasani et al., 1995). As a 
protein partner of SCL, the LIM-finger protein LMO2 can functionally interacts 
with SCL, and plays an indispensable role in primitive and definitive 
hematopoiesis (Orkin and Zon, 2008; Yamada et al., 1998). Furthermore, SCL 
and Lmo2 can form a multiprotein complex with Ldb1, E2A and Gata1 in 
erythroid cells. This complex recognizes and binds to a GATA-E-box DNA motif 
in which the SCL-E2A component interacts with E-box site and Gata1 binds to 
the GATA motif (Wadman et al., 1997). Those interactions indicate a broad 
physiological role of SCL and Lmo2 at distinct stages of hematopoiesis. 
The GATA family plays a crucial role during hematopoietic development. Gata2 
is highly expressed in hematopoietic stem and progenitor cells (Orlic et al., 
1995). Mice lacking Gata2 die from deficient primitive hematopoiesis and 
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severe anemia before embryonic day 10.5 (Tsai et al., 1994). Studies in 
Gata2-/+ animal model show its role in HSC generation and proliferation during 
embryo development, while HSC apoptosis and cellular quiescence in adult 
hematopoiesis respectively (Ling et al., 2004; Rodrigues et al., 2005). Many 
Gata2 mutations are identified in human disorders relative to myelodysplastic 
syndrome (MDS) and acute myeloid leukemia (AML) (Dickinson et al., 2011; 
Hsu et al., 2011; Ostergaard et al., 2011). In contrast, Gata1 and Gata3 are 
responsible for lineage specific differentiation. Gain and loss of function 
studies have shown that Gata1 effects erythroid cells (Fujiwara et al., 1996; 
Leonard et al., 1993), megakaryocytes, mast cells (Martin et al., 1990) and 
eosinophils (Zon et al., 1993), while Gata3 is required for T-cell development 
(Ting et al., 1996; Yamagata et al., 2000).  
Runx1 is a transcription factor that plays a critical role in the emergence of 
HSC by forming a core binding factor (CBF) complex with another 
non-DNA-binding protein CBFβ. Its disruption is embryonicaly lethal due to the 
absence of fetal liver hematopoiesis (Okuda et al., 1996). Using mice with 
Runx1-driven LacZ expression of Runx1 was first detected in mesenchymal 
cells from yolk sac where hematopoietic cells emerge: In addition, all HSCs 
show Runx1 expression in transplantation assays. Furthermore, Runx1 
dosage could affect the number of CD45 molecules, as well as the distribution 
of HSCs between CD45+, endothelial and mesenchymal cell pools (North et 
al., 1999; North et al., 2002). However, inducible Runx1 deletion in adult 
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hematopoietic cells revealed that it is critical for megakaryocytic maturation 
and B-, T- lyphopoiesis, but only limited role in HSC maintenance (Ichikawa et 
al., 2004). 
The differentiation of multipotent progenitors to committed precursor or mature 
cells involves numerous of lineage specific factors. They are not only 
promoting and maintaining their own lineage differentiation but also repressing 
factors favoring other lineages simultaneously.  
It has been reported that the overexpression of Gata1 or the ETS factor PU.1 
blocks myeloid or erythroid differentiation respectively. PU.1 is capable of 
suppressing erythroid gene transcription by inhibiting Gata1 DNA-binding 
capacity through direct protein-protein interactions, while Gata1 represses 
myeloid gene expression by directly binding to the PU.1 ETS domain (Nerlov 
et al., 2000; Zhang et al., 2000). This was later confirmed in vivo in zebrafish 
(Rhodes et al., 2005). Moreover, both PU.1 and Gata1 showed positive 
auto-regulation for their own expression (Fig 1.3.D) (Kobayashi et al., 2001; 
Okuno et al., 2005). Klf1 and Fli1 is another pair of cross-antagonistic 
transcription factors that antagonize each other in the regulation of erythroid 
versus megakaryocyte development (Starck et al., 2003). Recent study shows 
that Runx1 inhibits erythroid differentiation by shifting the balance between 
Klf1 and Fli1 in the direction of Fli1 (Kuvardina et al., 2015). Gfi1 blocks PU.1 
induced macrophage differentiation but increases granulocyte differentiation 
simultaneously by physically interacting with PU.1 (Dahl et al., 2007).  
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Figure 1.3 Network motifs in distinct lineage commitment (Vassiliou et al., 2012). 
Simplified examples of molecular activation and repression networks in myeloid (A), 
erythroid (B), and B-lymphoid (C) cells. Transcription factors are depicted in white, surface 
receptors in gray.  
 
After the lineage choice has been made, a set of distinct genes are needed to 
maintain the lineage commitment and produce the right number and type of 
mature cells. During erythropoiesis, besides the Gata/SCL/Lmo2/Ldb1 
transcriptional complex mentioned above, Gata1 binds Fog1 (friend of Gata1), 
TRAP220 (thyroid hormone receptor) and Sp1 by its N-terminal zinc finger as 
well, whereas binds CBP (CREB-binding protein), EKLF (erthroid Kruppel-like 
factor) and PU.1 by C-terminal zinc finger (Kim and Bresnick, 2007). As the 
cofactor of Gata1, Fog1 mediates the Gata2 displacement by interacting with 
Gata1 to promote terminal erythropoiesis (Fig. 1.3A) (Grass et al., 2003). 
EKLF is known as a determinant of hemoglobin switch, which binds CACCC 
motif of β–globin promoter directly (Miller and Bieker, 1993).  
The B-cell lineage commitment is mediated by a hierarchical network of key 
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transcription factors (Fig. 1.3B). Ikaros, E2A and PU.1 play critical roles in 
early lymphoid cell fate decision by functioning parallel or downstream of IL-7R 
signaling, and inducing early B-cell factor (EBF) and Pax5. E2A-deficient mice 
show a developmental block at the Prepro-B cell stage with dramatically 
reduced Rag1, mb-1, CD19 and lambda5 expression in fetal liver and 
compromised immunoglobulin D-J rearrangements (Bain et al., 1994; Borghesi 
et al., 2005). However, the B-cell differentiation arrest in the absence of E2A 
can be rescued with retroviral expression of EBF and ectopic Pax5 expression 
(Kwon et al., 2008; Seet et al., 2004). EBF is a major B cell transcriptional 
determinant that was suggested to act upstream of Pax5 and downstream of 
E2A, which binds to EBF promoter and activates its transcription (Smith et al., 
2002). More recently, distinct EBF isoforms were found due to two promoters, 
distal promoter, which is activated by IL-7 signaling, E2A and EBF, and 
proximal promoter, which is activated by Pax5, Ets1 and PU.1 (Roessler et al., 
2007). As the guardian of B cell identity and function, Pax5 is required for B 
lymphopoiesis in fetal and adult (Nutt et al., 1997). Interestingly, pro-B cells 
lacking Pax5 are able to differentiate into functional macrophages, 
granulocytes, dendritic cells, osteoclasts and natural killer cells in culture in the 
presence of lineage appropriate cytokines , suggesting that Pax5 plays a 
critical role in maintaining B cell fate by suppressing alternative lineage genes 
(Nutt et al., 1999). Signal transducer and activator of transcription 5 (STAT5) is 
activated by IL-7 signaling. Conditional deletion of Stat5 results in an early 
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block in B cell development, which could be rescued by EBF and Pax5 
expression. Moreover, many other transcription factors, including Foxo1, MYB, 
MIZ1 are required for proper B cell development (Clark et al., 2014).  
 
1.1.4 Epigenetic regulation of hematopoietic stem cell 
development 
While the focus on investigation of hematopoietic stem cell regulation has 
been put predominantly on the transcription factors, recent studies have 
indicated that the maintenance and differentiation of HSCs is also regulated by 
another intrinsic factor, the epigenetic modifications, which include DNA 
methylation, histone modification, chromatin remodeling, as well as micro and 
noncoding RNAs.  
 
DNA methylation 
DNA methylation is a biochemical process that involves the addition of a 
methyl group to the cytosine or adenine nucleotides and mediates 
transcriptional silencing. It generally takes place at the C5 position of CpG 
dinucleotides and catalyzed by two classes of DNA methyltransferases 
(Dnmts), the maintenance methytransferase (Dnmt1), which preserves 
methylation patterns during DNA replication, and de novo methyltransferases 
(Dnmt3a and Dnmt3b), which sets up DNA methylation early in development 
(Chuang et al., 1997; Okano et al., 1999). In contrast, Tet methylcytosine 
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dioxygenase Tet1, Tet2 and Tet3 have been identified as DNA demethylation 
catalases to convert 5-methylcytosine (5-mC) into 5-hydroximethylcytosines 
(5-hmCs), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) through 
consecutive oxidation reactions (Ito et al., 2010; Koh et al., 2011).  
Over the past decade, analyses of knockout mouse models helped  better 
understand the roles of DNA modifiers in hematopoiesis (Table 1.1). HSC 
lacking Dnmt1 activity exhibited increased transcription of key myeloerythroid 
associated regulators, including Gata1, ID2, and Cepba, but not lymphoid 
related factors, which lead to imbalanced myeloid and lymphoid differentiation 
(Broske et al., 2009a). Conditional ablation of Dnmt3a expanded HSC 
numbers while simultaneously impaired HSC differentiation ability in serial 
transplantations. Both hyper- and hypo-methylation occured in Dnmt3a-null 
HSCs. Some multipotency genes were selectively upregulated, including 
Runx1 and Gata3 while some differentiation factors were suppressed, such as 
Flk2, Ikaros and PU.1(Challen et al., 2012).  
 
Table1.1 Roles of DNA modifiers in hematopoiesis (Challen et al., 2012) 
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Histone modification 
As the basic unit of DNA packing, nucleosome consists of eight histone 
proteins and tightly wrapped DNA winds. The long tails of Histones can be 
modified by methylation, acetylation, phosphorylation and ubiquitination, which 
further alters the nucleosome structure either to be more compact or loose, 
which is associated with gene silencing or activation respectively. Acetylation 
and methylation are the most investigated histone modifications. Histone 
acetylation is executed by two classes of enzymes: histone acetyltransferases 
(HATs), which add acetylation marks to lysine residues, and histone 
deacetylases (HDACs), which remove acetyl group from histone tails. Similarly, 
histone methylation involves two opposing enzymes: histone 
methytransferases (HMTs) and histone demethylases (HDMs), leading to 
append or detach methyl groups respectively. 
Most histone modifiers have been identified in hematopoietic progenitors, in 
particular activating H3K4me, H3K9ac and repressive H3K7me marks. Some 
“bivalent” genes bear both conflicting modifications and are poised for 
expression in undifferentiated ES cells. During differentiation, either silencing 
of some genes or activation of gene expression will be conducted according to 
the tissue specific development (Fig. 1.5) (Spivakov and Fisher, 2007).  
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Figure 1.5 Bivalent epigenetic signatres in ES cells (Spivakov and Fisher, 2007). 
 
Methylation of H3K27 is catalyzed by polycomb repressor complex 2 (PRC2), 
which consists of embryonic ectoderm development (Eed), suppressor of 
zeste12 (Suz12) and the HMTase enhancer of zeste homologue 2 (Ezh2). 
Mice lacking functional PRC2 components display enhanced hematopoietic 
stem and progenitor cell (HSPC) activity, suggesting that PRC2 is restricting 
hematopoietic stem and progenitor pool size (Majewski et al., 2010). Some 
evidence indicates that Ezh2 can recruit all three Dnmts to specific 
PRC2-target promoters for DNA methylation in vivo, providing a link between 
DNA methylation and histone modification (Vire et al., 2006).  
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1.2 Zeb2 
1.2.1 Structure of Zeb2 
Zeb2, the Zinc Finger E-Box-Binding Homeobox 2, also named Sip1 and 
ZFHX1B, is a DNA-binding transcriptional regulator, which dimerize with E-box 
motif in different promoters. ZEB2 protein consists of 1,214 amino acids 
encoding by this gene belong to 2-handed zinc finger/homeodomain proteins 
family Zfh1. These proteins are characterized by a homeodomain flanked by 
two separated, highly conserved zinc finger clusters: one N-terminal and one 
C-terminal, which contain four and three zinc fingers respectively. Each zinc 
finger cluster can bind independently to CACCT(G) sequences in promoter 
regions of genes involved in differentiation and development, such as the 
Xenopus Xbra2 promoter, the human a4-integrin promoter and the E-cadherin 
promoter (Remacle et al., 1999; Verschueren et al., 1999). The Smad 
interacting domain (SID) binds to phosphorylated receptor activated Smads 
(R-Smads), which regulate TGF-and BMP signaling pathway. The CtBP 
interacting domain (CID) interacts with CtBP, which complex with histone 
deacetylases and methyltransferases (Sanchez-Tillo et al., 2011).  
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Figure 1.6 Motif of ZEB2 protein structure. SID, Smad-interacting domain; CID, 
CtBP-interacting domain. 
 
1.2.2 ZEB2 and MWS  
Mutations and deletions of ZEB2 may link to severe diseases, such as 
Mowat-Wilson syndrome (MWS), which characterized by a recognizable facial 
phenotype: widely spaced eyes, broad medial eyebrows, low hanging 
columella, prominent or pointed chin, uplifted earlobes with a central 
depression, open-mouthed expression. And structural anomalies which may 
include: Hirschsprung disease (Wakamatsu et al., 2001), congenital heart 
defects (particularly abnormalities of the pulmonary arteries and/or valves), 
urogenital anomalies (particularly hypospadias in males), agenesis or 
hypogenesis of the corpus callosum, Structure eye defects (microphthalmia 
and Axenfeld anomaly). In addition, functional differences including: moderate 
to severe intellectual disability, severe speech impairment with relative 
preservation of receptive language, seizures, growth retardation with 
microcephaly are common (Ariss et al., 2012; Meral et al., 2012; Saunders et 
al., 2009).  
Recently, Linda Pons et al report that spleen hypo-/aplasia is a part of the 
MWS phenotype and makes Zeb2 a possible candidate gene for primary 
17 
 
asplenia (Pons et al., 2014). Mowat-Wilson is caused by de novo 
heterozygous loss of function mutations including nonsense mutations, 
frameshift mutations, and deletions in Zeb2 at 2q22. Over 100 distinct 
mutations of ZEB2 have been described. By sequencing analyses, 
approximately 80% of Mowat-Wilson syndrome patients have a nonsense or 
frameshift mutation detectable, with the rest having gross deletions 
necessitating a dosage sensitive assay (Dastot-Le Moal et al., 2007; Saunders 
et al., 2009; Yamada et al., 2014). 
 
1.2.3 Zeb2, a repressor of SMADs 
TGFbeta/BMP signaling is highly conserved in different animal species. 
Ligands from extracellular environment transmit the signals to the cell by 
binding to type II receptors, which form heterodimers with type I receptors. 
This activates the receptor's serine/threonine kinase activity to phosphorylate 
and activate SMAD transcription factors, leads to nuclear translocation of 
Smad proteins, which activate or inhibit transcription of specific target genes 
(Massague, 2000).  
ZEB family of zinc finger factors were found to be involved in regulation of 
TGF-β/BMP signaling pathway. Both, ZEB-1 and ZEB-2 effect in opposite 
ways: ZEB-2 represses Smad-mediated transcriptional activation, while ZEB-1 
synergize with it. These antagonistic effects by the ZEB proteins arise from the 
differential recruitment of transcriptional coactivators and corepressors to the 
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Smads. In detail, ZEB-1 binds to p300 and promotes the formation of a 
p300-Smad transcriptional complex, while ZEB-2 acts as a repressor by 
recruiting CtBP (Postigo et al., 2003). 
 
1.2.4 ZEB2 induce EMT 
Epithelial to mesenchymal transition (EMT), a process of the 
transdifferentiation of epithelial cells into motile mesenchymal cells, is integral 
in development, wound healing and stem cell behaviour, and contributes 
pathologically to fibrosis and cancer progression. This switch in cell 
differentiation and behaviour is mediated by key transcription factors, including 
SNAIL, zinc-finger E-box-binding (ZEB) and basic helix-loop-helix transcription 
factors, the functions of which are finely regulated at the transcriptional, 
translational and post-translational levels.(Lamouille et al., 2014) 
Loss of E-cadherin expression is a hallmark of EMT. E-cadherin is a central 
component of cell-cell adhesion and is required for the formation of epithelia in 
the embryo and to maintain epithelial homeostasis in the adult. Loss of 
E-cadherin is consistently observed at sites of EMT during development and 
cancer (Thiery, 2002). The loss of E-cadherin increases tumor cell 
invasiveness in vitro and contributes to the transition of adenoma to carcinoma 
in animal models (Thiery, 2002). ZEB2 can bind to the E-cadherin promoter 
and downregulate E-cadherin and other tight junction related genes’ 
transcription. Thus  ZEB2 plays an important role in inducing the EMT 
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process (Comijn et al., 2001; Vandewalle et al., 2005).  
Mechanistically, ZEB2 have been found to upregulate integrin alpha5 
expression through cooperation with Sp1 to induce invasion during the EMT of 
human cancer cells (Nam et al., 2012). Meanwhile, ZEB2 was found to be 
regulated by MicroRNAs, which eventually can affect the  EMT process. 
MicroRNAs are a large family of small (21–23-nt) RNAs which can regulate 
gene expression by interacting with multiple mRNAs and inducing either 
translational suppression or degradation of mRNA. They have been implicated 
in regulating complex physiological processes such as embryogenesis 
(Wienholds et al., 2005), organ development (Yi et al., 2006), and oncogenesis 
(Esquela-Kerscher and Slack, 2006).The miR-200 family (miR-200a, 
miR-200b, miR-200c, miR-141 and miR-429) and miR-205 regulate epithelial 
to mesenchymal transition by targeting ZEB1 and ZEB2. These microRNAs 
was found to be lost in invasive breast cancer cell lines with mesenchymal 
phenotype. Expression of the miR-200 family was also lost in regions of 
metaplastic breast cancer specimens lacking E-cadherin (Gregory et al., 2008). 
The miR-200 family inhibits EMT and cancer cell migration by direct targeting 
of E-cadherin transcriptional repressors Zeb1 and Zeb2 (Korpal et al., 2008; 
Park et al., 2008). Beyond that, in Snail1-induced EMT, synthesis of Zeb2 is 
up-regulated, Snail1 does not affect the synthesis of Zeb2 mRNA, but prevent 
the processing of a large intron located in its 5'-untranslated region (UTR). This 
intron contains an internal ribosome entry site (IRES) necessary for the 
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expression of Zeb2. Maintenance of 5'-UTR Zeb2 intron is dependent on the 
expression of a natural antisense transcript (NAT) that overlaps the 5' splice 
site in the intron. Ectopic overexpression of this NAT in epithelial cells prevents 
splicing of the Zeb2 5'-UTR, increases the levels of Zeb2 protein, and 
consequently down-regulates E-cadherin mRNA and protein (Beltran et al., 
2008). 
miR-200a/ZEB2 pathway not only regulates EMT but also stem-like transition 
in nasopharyngeal carcinoma cells. Stable knockdown of miR-200a promotes 
the transition of epithelium-like CNE-1 cells to the mesenchymal phenotype. 
More importantly, it also induced several stem cell-like traits, including 
CD133(+) side population, sphere formation capacity, in vivo tumorigenicity in 
nude mice, and stem cell marker expression (Xia et al., 2010). For induced 
pluripotent stem cell (iPS),members of the miR-200 family are unique 
mediators of the reprogramming factors Oct4/Sox2, the miR-200/ZEB2 
pathway as one critical mechanism of Oct4/Sox2 to induce somatic cell 
reprogramming at the early stage (Wang et al., 2013). 
 
1.2.5 ZEB2 in cancer 
As EMT is also a widespread biological phenomena in cancers, ZEB2 was 
found to play an important role in initiation and progression in several kinds of 
cancer (De Craene and Berx, 2013). Overexpression of ZEB2 at the invasion 
front of colorectal cancer is an independent prognostic marker and regulates 
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tumor invasion in vitro (Kahlert et al., 2011). By transactivating ZEB2 and 
VersicanV1 expression, Forkhead box Q1 will promotes hepatocellular 
carcinoma metastasis (Xia et al., 2014; You et al., 2011). In melanoma cell, 
ZEB2-MITF-ZEB1 transcriptional network controls melanogenesis and 
melanoma progression (Denecker et al., 2014). In prostate cancer, ZEB2 
expression was regulate by Androgen receptor and its implications in 
epithelial-to-mesenchymal transition (Jacob et al., 2014). 
ZEB2 protein protects cells from DNA damage-induced apoptosis and has 
independent prognostic value in bladder cancer (Sayan et al., 2009). ZEB2 
overexpression (examined by IHC) is also an independent biomarker for the 
poor prognosis of patients with renal cell carcinoma (Fang et al., 2013). 
 
1.2.6 Zeb2 in hematopoietic system 
In hematopoietic system, high Zeb2 mRNA expression levels was detected in 
HSCs and hematopoietic progenitor cells (HPCs). Previously, Tie2-Cre and 
Vav-iCre based conditional Zeb2 deletion were used to study the role of Zeb2 
in hematopoietic system. Zeb2−/ΔTie2-Cre displayed an early lethality around 
E12.5-E13.5 due to intracerebral hemorrhages. However, no obvious loss of 
HSCs were observed in knockout mice before E11.5 compared with littermate 
controls, suggesting that Zeb2 is not essential for HSC formation. Vav-iCre 
mediated aproach of gene deletion, wich is more HSC specific, revealed 
similar defects in hematopoiesis with early letality as Zeb2−/ΔTie2-Cre knockouts. 
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In addition, Zeb2-ablated hematopoietic precursor cells showed severe block 
in multiple hematopoietic lineages. After colonizing the fetal liver 
Zeb2-deficient hematopoietic stem/progenitor cells exhibited altered adhesive 
and homing properties and an inability to reenter the blood circulation and 
colonize the bone marrow cavity. These results indicate critical roles of Zeb2 in 
embryonic hematopoiesis and suggest that Zeb2 may also be important for 
adult hematopoiesis (Goossens et al., 2011). Moreover, there is increasing 
evidence suggesting that overexpression of Zeb2 is involved in hematopoietic 
malignancies. Retroviral insertional mutagenesis identified Zeb2 activation as 
a novel leukemogenic collaborating event in CALM-AF10 transgenic mice. 
89% of mice with a Zeb2 integration developed B-cell acute lymphoblastic 
leukemia (ALL) (Caudell et al., 2010). A recent study has reported a 
recurrent t(2;14)(q22;q32) chromosomal translocation, targeting Zeb2, in early 
T-cell precursor leukemia (ETP-ALL) indicating that sustained Zeb2 
expression initiates T-cell leukaemia. Moreover, Zeb2-driven mouse leukaemia 
exhibits an enhanced leukaemia-initiation potential and activated Janus kinase 
(JAK)/ STAT signalling through transcriptional activation of IL7R (Goossens et 
al., 2015). Above studies point to a possible importance of Zeb2 for 
maintenance of normal hematopoiesis. 
 
1.2.7 Preliminary work 
In order to investigate the physiological role of Zeb2 in the regulation of 
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homeostasis in adult hematopoietic system, we use the interferon sensitive 
Mx1-Cre based inducible knockout model to generate Zeb2 deficient mice, 
where Zeb2 was deleted in adult hematopoietic cells upon Poly (I:C) 
administration. Our previous work revealed that eight weeks following Zeb2 
deletion mice exhibited significantly lower number of B-lymphocytes, 
monocytes, platelets and erythrocytes in peripheral blood, whereas the 
number of granulocytes was slightly increased and T-lymphocytes was not 
different to controls. However, further analyses of the immature bone marrow 
compartment revealed an accumulation of HSPC (defined as lineage-, cKit+, 
Sca1+, LKS) and HSC (LKSCD48-CD150+) populations. Those changes were 
not due to altered apoptotic events or proliferation rates. Within the different 
myeloid restricted progenitor subpopulations we observed a shift towards 
increased frequency of MEP and reduced GMP. However, no change in the 
percentage of CLP was detectable. Similar but more pronounced phenotype 
were observed in competitive and non-competitive transplant settings, 
indicating that the hematopoietic lineage impairment is not due to self-renewal 
but intrinsic differentiation defects of stem cells. Moreover, Zeb2 ablation in the 
hematopoietic compartment led to a phenotype with several features 
reminiscent of myeloproliferative disorders in human, such as bone marrow 
fibrosis, splenomegaly and extramedullary hematopoiesis.  
To determine downstream targets that might be responsible for the complex 
differentiation impairment phenotype in most hematopoietic lineages in the 
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absence of Zeb2 a global gene expression analyzes focusing on the HSPC 
containing bone marrow subset were performed. Several molecules involved 
in the Wnt signaling pathway stood out and suggested increased Wnt signaling 
activity in Zeb2-deficient HSPC. Surprisingly, when Zeb2 and β-catenin were 
deleted simultaneously in the hematopoietic compartment using the same 
conditional knockout strategy, all double knockout mice died very shortly after 
Poly (I:C) administration. No rescue or difference was observed in Zeb2 
deletion mice with or without haploinsufficiency of β-catenin (data not 
published).  
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1.3 research goals  
Our previous results demonstrated that Zeb2 is essential for normal 
hematopoietic stem cell differentiation. However, given the complex phenotype 
of insufficient blood cell maturation in multiple lineages at different stages of 
differentiation and the inability to rescue the phenotype by affecting the 
expression level a single putative downstream targets we reasoned, that the 
observed changes would probably not be caused by one downstream target, 
but rather due to a broad spectrum of epigenetic changes.  
The goal of this thesis is to understand the role of Zeb2 in differentiation 
process of different hematopoietic lineages at a molecular level. We first aimed 
to define at which stage of maturation the bone marrow cells of different 
lineages exhibited a differentiation block. Next we investigated the gene 
expression profile of putative target genes known to be essential at the 
particular developmental stage. Thirdly, we aimed to test whether Zeb2 is 
involved in in epigenetic regulation by gene expression analyses of known 
epigenetic modulators specifically in sell subsetts where the differentiation was 
blocked. Finally we performed functional analyses to confirm alterations in cell 
signaling pathways.   
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2. Materials and Methods 
2.1 Materials 
2.1.1 Laboratory equipments 
 
Equipment Model Supplier 
Autoclave CX-150 Systec, Wettenberg, 
Germany 
Centrifuges 5810R, 5430R, miniSpin 
plus 
Eppendorf, Hamburg, 
Germany 
Mini Star VWR, Radnor, PA 
Varifuge 3.0R Heraeus, Hanao, Germany  
CO2 Incubator MCO-18AIC (UV) SANYO, Moriguchi, Japan 
Electrophoresis 
chamber 
PerfectBlue Gel System 
Mini 
Peqlab, Erlangen, Germany 
Flow cytometer FACS CantoII BD, Heidelberg, Germany 
Gel imaging 
system 
ChemiDoc XRS+ Bio-Rad, Hercules, CA 
Hemocytometer Hemavet 950 Drew Scientific, USA 
Heating Magnetic 
stirrer 
Aluminum Hot Plate 
Stirrer - ARE 
VELP Scientifica, Usmate, 
Italy 
Laminar flow hood MSC-Advantage Thermo Scientific, Waltham, 
MA 
Light microscope Eclipse TS100 Nikon, Tokyo, Japan 
MACS Separator QuadroMACSTM 
Separator 
Miltenyi, Gladbach, 
Germany 
Microwave NN-E245W Panasonic, Kadoma, Japan  
Microplate reader Infinite 200 TECAN, Mannedorf, 
Switzerland 
PCR cycler Mastercycler pro Eppendorf, Hamburg, 
Germany 
Power supply EV202 Consort, Turnhout, Belgium 
Electrophoresis 
chamber 
XCell SureLock 
Mini-Cell 
Thermo Scientific, Waltham, 
MA 
Electrophoresis 
chamber 
Mini-PROTEAN Tetra 
Cel 
Bio-Rad, Hercules, CA 
Real-Time PCR 
cycler 
Mastercycler Realplex Eppendorf, Hamburg, 
Germany 
Roller mixer STR9 Stuart, Staffordshire, UK 
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Scale SBA 53 Scaltec, Heiligenstadt, 
Germany 
Shaker-Incubator ES-20 BioSan, Riga, Latvia 
Spectrophotometer Nanodrop 2000 Thermo Scientific, Waltham, 
MA 
Thermomixer Thermomixer comfort Eppendorf, Hamburg, 
Germany 
Vortexer ZX3 Vortex mixer VELP Scientifica, Usmate, 
Italy 
Waterbath WNB 7-45 Memmert, Nuremberg, 
Germany 
X-ray generator   RS-2000 biological 
irradiator 
Rad source, Suwanee, GA 
 
2.1.2 Consumable materials 
 
Item Supplier 
Alcohol pads Braun 
Cell culture dishes (10cm) Greiner Bio-one 
Cell culture flasks (25/ 75/ 175 cm) Greiner Bio-one 
Cell culture plates (6-well, 12-well, 24-well, 
96-well) 
BD 
Cell strainer 70µm Nylon Corning 
Disposable scalpel Feather 
Filter tips (10 μL, 200 μL, 1000 μL) Nerbe Plus 
Falcon tubes 15mL Corning 
Falcon tubes 50mL Greiner Bio-one 
Falcon tube with cell stainer snap cap Corning 
Falcon tube with snap cap Corning 
FACS tubes Röhren 
Hypodermic safety needle Magellan 
LD Columns Miltenyi Biotec 
Leukosilk BSN medical 
Micro-fine U-40 insulin BD 
Microtainer K2E Tubes BD 
Microtubes (1mL, 1.5mL) Sarstedt 
Microtubes (0.6mL) Axygen 
Needles BD 
Parafilm Pechiney 
PCR reaction tubes Biozym Scientific 
Pipette (5mL, 10mL) Greiner Bio-one 
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real-time PCR film Eppendorf 
real-time PCR plate Applied Biosystems 
Refill pipette tips (10μL, 200μL,) Nerbe Plus 
Safe-lock tubes (0.5mL) Eppendorf 
Sterile filter 0.22 µm Millipore 
Syringe (2ml, 5ml, 10 mL) BD 
 
2.1.3 Chemicals, reagents and kits 
 
Item Supplier 
2 x M-PCR OPTITM Mix (Dye Plus) Biotool 
2x SYBR Green qPCR Master Mix Biotool 
4-12% Bis-Tris Protein Gels Life Technologies 
Agarose Peqlab 
β-Mercaptoethanol Sigma 
BCA Protein Assay Kit Life Technologies 
BSA (Bovine serum albumin) 
Molecular Probes, 
Invitrogen 
BrdU Flow Kit BD 
cDNA Reverse Transcription Kit Life Technologies 
CellTrace™ CFSE Cell Proliferation Kit Life Technologies 
Dexamethasone Sigma 
Dimethyl sulfoxide (DMSO) Sigma Aldrich 
Distilled water Gibco, Life technologies 
ECL Prime Western Blotting Detection 
Reagent GE Healthcare 
Ethylendiamidtetraacetat (EDTA) Sigma 
Ethanol (70%, 100%) Merck 
Ethidium bromide   Sigma 
FACS Lysing Solution/Buffer BD 
Fetal bovine serum (FBS) PAA 
Formaldehyde (4%, 10%) Merck 
G-CSF Amgen 
Glycin Roch 
LDS Sample Buffer (4X) Life Technologies 
Methanol Merk 
Mouse IGF-1 eBioscience 
Mouse IL-3 Miltenyi Biotec 
Mouse IL-6 R&D Systems 
Mouse IL-7 Miltenyi Biotec 
Mouse SCF Peprotech 
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Non-fat milk powder Roche 
PCR Tail Lysing Reagent Peqlab 
Pre-Separation Filter, 30 μm Miltenyi Biotec 
Penicillin-streptavidin, 100x Gibco, Life Technologies 
Perm/Wash Buffer BD 
Perm/Wash Buffer I BD 
Perm/Wash Buffer III BD 
Phenylhydrazine (PHZ) Sigma 
Phosphate-buffered saline (PBS) Gibco, Life Technologies 
Poly(I) Poly (C) Double Strand GE healthcare 
Proteinase K Roch 
Pure Link RNA mini Kit Life Technologies 
SDS Running Buffer (20X) Life Technologies 
Sodium chloride 0.9% Ecotainer 
Streptavidin Microbeads Miltenyi 
Thiazol orange (TO) Sigma Aldrich 
Tris Sigma Aldrich 
Tris-HCl Sigma Aldrich 
Tween-20 Sigma Aldrich 
 
2.1.4 Antibodies 
 
Antibodies for flow cytometry     
Specificity  Fluorochrome Dilution Suplier  
7-AAD     BD 
anti-rabbit FITC 1:1000   
BrdU FITC 1:50 BD 
CD11b/Mac1 eFluor450 1:500 eBioscience 
CD19 APC 1:500 eBioscience 
CD24 PE-Cy7 1:200 eBioscience 
CD34 FITC 1:200 eBioscience 
CD43 PE 1:500 eBioscience 
CD44 PE 1:500 eBioscience 
CD45 
Biotin 1:200 eBioscience 
PE 1:1000 eBioscience 
CD45.1 PE 1:200 eBioscience 
CD45.2 FITC 1:200 eBioscience 
CD45R/B220 PerCP-Cyanine5.5 1:500 eBioscience 
CD71 APC 1:500 eBioscience 
CD117/c-Kit APC 1:100 eBioscience 
CD127/IL-7R APC-eFluor780 1:200 eBioscience 
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CD135/Flt-3 PE 1:500 eBioscience 
DAPI   1:2000 eBioscience 
Gr1 eFluor660 1:500 eBioscience 
Ki67 FITC 1:50 eBioscience 
Lineage cocktail Biotin 1:50 BD 
IgD FITC 1:500 eBioscience 
IgM PE 1:500 eBioscience 
Phospho-Akt (Ser473) 1:100 Cell Signaling 
Phospho-Erk1/2 (Thr202/Tyr204) 1:200 Cell Signaling 
Phospho-Stat3 (Tyr705) 1:200 Cell Signaling 
Phospho-Stat5 (Tyr694) 1:400 Cell Signaling 
Sca-1 PE-Cy7 1:300 eBioscience 
Streptavidin 
eF450 1:500 eBioscience 
PE 1:1000 eBioscience 
PerCP-Cy5.5 1:500 eBioscience 
Ter119 APC-eFluor780 1:500 eBioscience 
 
Antibodies for western blot    
Antigen coupling Host Dilution Suplier 
β-actin   Mouse 1:1000 Cell Signaling 
Erk   Rabbit 1:1000 Cell Signaling 
GAPDH   Rabbit 1:1000 Cell Signaling 
Phospho-Akt (Ser473)   Rabbit 1:1000 Cell Signaling 
Phospho-Erk1/2 
(Thr202/Tyr204)   Rabbit 1:1000 Cell Signaling 
Phospho-Stat3 
(Tyr705)   Rabbit 1:2000 Cell Signaling 
Phospho-Stat5 
(Tyr694)   Rabbit 1:1000 Cell Signaling 
Mouse IgG HRP Rabbit 1:5000 
Jackson 
ImmunoResearch 
Rabbit IgG HRP Rabbit 1:5000 
Jackson 
ImmunoResearch 
Stat3   Rabbit 1:2000 Cell Signaling 
Stat5   Rabbit 1:1000 Cell Signaling 
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2.1.5 Primers 
 
Primers for qRT-PCR 
Oligoname Sequence 5' -> 3' 
β-Actin-F AGTGTGACGTTGACATCCGTA 
β-Actin-R GCCAGAGCAGTAATCTCCTTCT 
Bcl-2-F TGAGTACCTGAACCGGCATCT 
Bcl-2-R GCATCCCAGCCTCCGTTAT 
Blimp1-F ACACACAGGAGAGAAGCCACATGA 
Blimp1-R TCGAAGGTGGGTCTTGAGATTGCT 
CDK4-F TCGAAAGCCTCTCTTCTGTG 
CDK4-R TACATCTCGAGGCCAGTCAT 
Cxcr4-F GAAGTGGGGTCTGGAGACTAT 
Cxcr4-R TTGCCGACTATGCCAGTCAAG 
Dnmt1-F CCTAGTTCCGTGGCTACGAGGAGAA 
Dnmt1-R TCTCTCTCCTCTGCAGCCGACTCA 
Dnmt3a-F GAGGGAACTGAGACCCCAC 
Dnmt3a-R CTGGAAGGTGAGTCTTGGCA 
Dnmt3b-F AGCGGGTATGAGGAGTGCAT 
Dnmt3b-R GGGAGCATCCTTCGTGTCTG 
E2A-F CCCGGATCACTCCAGCAATAA 
E2A-R TGGAGACCTGCATCGTAGTTG 
EBF-F CTTGCTAACACTTCGGTCCAT 
EBF-R ACCTTGATTGGTGGCTTGTG 
Eed-F AATGTGGCGCGGCTATTC 
Eed-R CGAAGTCGATCCCATCGC 
Ezh2-F CCAGACTGGTGAAGAGTTGTTTT 
Ezh2-R CAAGGGATTTCCATTTCTCG 
Fli1-F GGACTGATCGTCACTCACCA 
Fli1-R AATCTGAAGGGGCTACGAGG 
Fog1-F CTTGGGGCTGCTGTCCAT 
Fog1-R GTCCAGGAGGAAACAGAGCA 
Foxo1-F AGGAACTGAGGAGCAGTCCA 
Foxo1-R ATGATTCCCAATGGCACAGT 
GAPDH-F AGGTTGTCTCCTGCGACTTCA 
GAPDH-R GGTGGTCCAGGGTTTCTTACTC 
Gata1-F ACTGGCCTACTACAGAGAAGC 
Gata1-R GTAGAGTGCCGTCTTGCCATA 
Gata2-F CACCCCGCCGTATTGAATG 
Gata2-R CCTGCGAGTCGAGATGGTTG 
Gata3-F TTTACCCTCCGGCTTCATCCTCCT 
Gata3-R TGCACCTGATACTTGAGGCACTCT 
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G-CSFR-F GTTTTGTGGGGAGTGGGGAT 
G-CSFR-R CCACATGCTGGAGACCAGAG 
Hdac1-F CTGTCCGGTATTTGATGGCT 
Hdac1-R CACGAACTCCACACACTTGG 
Hdac2-F GGCGGCAAGAAGAAAGTGTGC 
Hdac2-R GGCATCATGTAGTCCTCCAGC 
Id2-F GACCCGATGAGCCTGCTATAC 
Id2-R GGTGCTGCAGGATTTCCATCT 
Id3-F CTCTTAGCCTCTTGGACGACAT 
Id3-R GATCGAAGCTCATCCATGCCCT 
Ikaros-F TGAGGGTCAAGACATGTCCCAAGT 
Ikaros-R TCACTCTTGGAGTTCTGCTGTGCT 
IL-3Rα-F TGGGCGCCACTCAGGAAC 
IL-3Rα-R GTCACAGCAGTGGGTGGAG 
IL-6Rα-F TGAATGATGACCCCAGGCAC 
IL-6Rα-F ACACCCATCCGCTCTCTACT 
IL-7R-F ACGATCACTCCTTCTGGTGC 
IL-7R-R GCATTTCACTCGTAAAAGAGCC 
Pbx1-F AGGACATCGGGGACATTTTAC 
Pbx1-R CATTAAACAAGGCAGGCTTCA 
Klf1-F GACGATGTCCAGTGTGCTTC 
Klf1-R CTACTCCAAGAGCTCGCACC 
Lmo2-F  AGGAGAGACTATCTCAGGCTTTT 
Lmo2-R TTGAAACACTCCAGGTGATACAC 
LSD1-F GCCTGTTTCCCAGACATCAT 
LSD1-R CAGCTGGATCTTTGGGTTGT 
LRF-F TCTTCTCGGAAGAGAGGGAA 
LRF-R CAGAAGGCCTCAGAATCCTC 
Mi-2β-F CCTCATTGTGGATGAAGCC 
Mi-2β-R GAAAGTTGAGCAGATGAAACAG 
Mpl-F ACCTTTGGAACCCGGTATGTG 
Mpl-R CTGTGGAGAGCAGCTGAATG 
Nr4a2-F ATTGCTGCCCTGGCTATGGTCA 
Nr4a2-R CAGGTAGTTGGGTCGGTTCAAACC 
Pax5-F AGCAGCCCCCCAATCAG 
Pax5-R TGCGTCACGGAGCCTGTA 
Prdm16-F AGATGAACCAGGCATCCACTCGAA 
Prdm16-R ACTTCCCGGCTAAGCTGTCATCAT 
Runx1-F GCAGGCAACGATGAAAACTACT 
Runx1-R GCAACTTGTGGCGGATTTGTA 
Runx3-F ACCACGAGCCACTTCAGCAG 
Runx3-R CGATGGTGTGGCGCTGTA 
SCL-F CATTCACATTCTGCTGCCTC 
SCL-R AACAACAACCGGGTGAAGAG 
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Sip1-F GGCAAGGCCTTCAAGTACAA 
Sip1-R AAGCGTTTCTTGCAGTTTGG 
Suz12-F CTCAGGATATACATCGCCAACCT 
Suz12-R TGTTCTTTTTGGCCTGCAAAC 
Tet-1-F ACACAGTGGTGCTAATGCAG 
Tet-1-R AGCATGAACGGGAGAATCGG 
Tet2-F TGTTGTTGTCAGGGTGAGAATC 
Tet2-R TCTTGCTTCTGGCAAACTTACA 
Tet-3-F TCTCTGAAGGGTGGATTGTCC 
Tet-3-R CCCAGCACCGAGTAGCTTTC 
TBP-F TCTATTTTGGAAGAGCAACAAAGAC 
TBP-R GAGGCTGCTGCAGTTGCTA 
YWHAZ-F AGACGGAAGGTGCTGAGAAA 
YWHAZ-R TCAAGAACTTTTCCAAAAGAGACA 
 
Primers for genotyping 
Oligoname Sequence 5' -> 3' 
Zeb2-Intron6F GAACTAGTTGAATTGGTAGAATCAATGGGG 
Zeb2-Intron6R GTAAAGGCTCTCTACGCCTTTTTCAGTTAG 
Zeb2-Intron7F AAGCATGTCGGTAAGCTGACCAACTACTAG 
MxCreF CATGTGTCTTGGTGGGCTGAG 
MxCreR CGCATAACCAGTGAAACAGCAT 
 
2.1.6 Buffers and solutions 
 
Item Composition Storage 
IL-7 10ng/μL 2μg IL-7 -80°C 
  200μL dd H2O   
PHZ 1.1g/mL 11mg phenylhydrazine 4°C 
  10mL H2O   
Poly(I) Poly(C)  265mg Poly(I) Poly(C)  -80°C 
  180mL 0.9% sodium chloride   
Proteinase K 20mg/mL 100mg Proteinase K -20°C 
  5mL 10mM Tris buffer   
Staining buffer 500μL FBS 4°C 
  49.5mL PBS   
Tris buffer 10mM 0.08g Tris-HCl RT 
  50mL H2O   
TAE buffer 50x 242g Tris  RT 
 57,1 ml Acetic Acid  
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 100 ml EDTA (0,5 M, pH 8,0)  
  fill up to 1000 ml with water.   
TAE buffer 1x 40mL TAE buffer 50x RT 
  1960mL H2O   
TBS-T stock 10x 24.2g Tris RT 
 80g NaCl  
 adjust pH to 7.6  
  700ml H2O   
TBS-T1x 100ml TBS-T stock 10x RT 
 2ml Tween-20  
  fill up to 1000 ml with water.   
TO stock 10000x 10mg thiazol orange -20°C 
  10mL methanol stable for 2m 
TO 1x 5μL TO stock 10000x fresh prepared 
  50mL PBS   
Transfer buffer stock 
10x 
150.14g Glycin RT 
 30.285g Tris  
 adjust pH to 8.3  
  fill up to 1000 ml with water.   
Transfer buffer 1x 100ml Transfer buffer stock 10x RT 
 200ml methanol  
  fill up to 1000 ml with water.   
 
2.1.7 Softwares 
  
Software Purpose 
BD FACSDiva 
Application setup, data acquisition, and data analysis 
on BD FACSCanto II 
Flowjow Viewing and analyzing flow cytometric data 
GraphPad Prism 5 Graphing, statistical analyses and data organization 
Image Lab 
Image acquisition and analyzing gel and blot features. 
Runs with gel ChemiDoc XRS+ imaging system. 
Nanodrop Quantification of RNA  
qBase plus real-time PCR data analysis 
Realplex Thermal cycling program setup and data acquision 
TierBase 
a database for recording, raisiong and breeding 
laboratory animals as well as the documentation of 
animal experiments 
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2.2 Methods  
2.2.1 Mice 
Mice harboring a floxed Zeb2 allele were described previously (Higashi et al., 
2002). Zeb2 fl/fl mice were mated to Mx1-Cre mice, which expressing an 
interferon-inducible Cre recombinase, to generate Zeb2 fl/fl harboring or not 
the Mx1-Cre transgene. Genotyping was performed by PCR, the temperature 
cycle conditions of which was described below. Primers are listed above. 
Conditional Zeb2 knockout mice were induced 3 times by intraperitoneal 
injection with 12.5 ug polyinosinic-polycytidylic acid (poly I:C) dissolved in 
0.9% NaCl/ g body weight on alternate days in 6-8 weeks old mice. Mice were 
analyzed 2-3 months after the first injection. To induce a hemolytic anemia, 
mice were injected subcutaneously with 30mg/kg body weight 
phenylhydrazine (PHZ; Sigma-Aldrich) for 2 consecutive days. Mice were bled 
on days 0, 2, 4, 7, 10, 14 for hematocrit and reticulocyte count measurements. 
The C57BL/6J (CD45.2) mice were purchased from Charles River. All animal 
experiments were approved by the Federal office for Nature, Environment and 
Consumer protection North Rhine Westphalia (Landesamt für Natur, Umwelt 
und Verbraucherschutz NRW). 
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Figure 2.1 Schematic representation of Zeb2 locus and strategy for Zeb2 conditional 
knockout (Higashi et al., 2002). NZF: N-terminal zinc finger clusters, CZF: C-terminal zinc 
finger clusters, HD: homeodomain-like sequence, CtBP: CtBP binding sites, SB: 
Smad-binding domain. The gray boxes represent coding exons. 
 
Table 2.1 PCR program for genotyping Mx1-Cre and Zeb2 allels 
Temperature (°C) Time Cycles 
94 5 min 1 
94 (Denaturing) 20 sec 
38 
58 (Mx1-Cre)/ 52(Zeb2) 
(Annealing) 30 sec 
72 (Elongation) 40 sec 
72 5 min 1 
4 -- 1 
 
2.2.2 Blood 
Peripheral blood was obtained from the tail vein and collected in EDTA-coated 
microtainers (BD Biosciences). Blood parameters were counted by an 
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automated hemocytometer (Hemavet 950; Drew Scientific). The reticulocyte 
counts were measured by thiazole orange (TO, sigma) staining as previously 
described.(Lee et al., 1986) 
 
2.2.3 Bone marrow transplantation 
2x106 bone marrow mononuclear cells from 8 to 12 week old control (CD45.1) 
and Zeb2-deficient (CD45.1) littermates were isolated and transplanted into 
female C57BL/6 (CD45.2) recipients. Recipients were lethally irradiated with 
12-Gy in split doses. Hematologic parameters were monitored by analysis of 
peripheral blood at 4, 8, 12 weeks after transplantation. 12 weeks 
posttransplantation, hemolytic anemia was induced as described above. 
 
2.2.4 Flow cytometry and cell sorting 
A single-cell suspension of bone marrow or spleen was prepared by staining 
buffer and incubated with specific cell surface markers for 20 minutes at 4 
degree. The antibodies for different panels were described above. 
7-Aminoactinomycin D (7-AAD; BD Biosciences) was used to exclude dead 
cells before measurement. For BrdU incorporation assay, mice were injected 
intraperitoneally with BrdU (BD) at a dosage of 150ug/g of body mass 1 hour 
before sacrifice. The intracellular BrdU was stained using a BrdU-FITC flow kit 
(BD Biosciences) according to the manufacturer´s protocol after erythroid cells 
were staged as described above. The DNA content was assessed by 7-AAD. 
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Cells were measured by FACS CantoII (BD Biosciences) and analyzed by 
Flowjo. Ter119+CD71high, Prepro-B, LKS, progenitor and myeloid population 
were sorted by FACSAria III (BD Biosciences).  
 
2.2.5 CFU-E and BFU-E  
Freshly isolated bone marrow and spleen cells were counted by Hemavet. For 
CFU-E detection and quantification, 1*105 Bone marrow or 1*106 spleen cells 
were mixed with M3334 MethoCult methylcullulose media and seeded into one 
well of 12-well plates. Colonies were counted two days after incubation. For 
BFU-E detection, whole bone marrow cells and spleen cells were seeded into 
12-well plates at a density of 1*104 cells/well and 1*105 cells/well in M3434 
MethoCult methylcullulose media. Following incubation for 7 days at a 37°C 
humidified incubator with 5% CO2, BFU-E were quantified.    
 
2.2.6 Quantitative Real Time Polymerase Chain Reactions 
(qRT-PCR) 
Reagents and kits 
All steps and procedures have been established following the MIQE 
guidelines. Total RNA was extracted using the Ambion PureLink RNA mini Kit. 
RNA quality and concentration was measured using a Nanodrop machine. 
cDNA was obtained by reverse transcription using the high capacity cDNA 
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transcription kit (life technologies). The qPCR was carried out using the 
TaKaRa Syber Premix Ex Taq kit on an Eppendorf Mastercycler ep Realplex 
machine. Primers sequences were either found in the literature, obtained from 
the RTPrimerDB database or developed in our lab. All sequences are 
exon-spanning and were blasted in order to ascertain specificity. Secondary 
structure formation was also analysed. They were chosen to work in a 
temperature range of 59 to 61°C, resulting in an amplicon of 80 to 200 bases. 
Primers were synthesized by Eurofins MWG Operon (Ebersberg, Germany).  
 
RNA and cDNA preparation 
After RNA was extracted according to the manufacturer’s instructions, its 
quality and concentration was measured using the Nanodrop. If samples were 
contaminated with DNA, they were subjected to DNase digestion using the 
PureLink Amplification grade DNase I according to the manufacturer’s 
instructions. Aliquots of the samples were then diluted to 10 ng/µl working 
concentration. Stock solutions were stored immediately after dilution at   
-80°C. Working solutions were stores immediately at -20°C. For the reverse 
transcription, 5 µl of RNA per sample were used in a reaction volume of 20 µl 
according to the manufacturer’s instructions. The reactions were carried out 
using an eppendorf cycler. cDNA was then either immediately used for qPCR 
or stored at -20°C. 
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qPCR 
qPCR reactions were done in 96 well twin.tec plates covered by a Masterclear 
real-time PCR adhesive film, both supplied by Eppendorf. The program is 
listed in table 2.2. In each well were pipeted 2 µl of cDNA and 18 µl of Syber 
Premix reaction mix containing forward and reverse primers. All Samples were 
measured at least in duplicates. The amplification program used always 
included a melting curve analysis at the end to ascertain that the amplification 
was target specific. 
For each new type of sample, a panel of 10 reference genes were analysed 
using the geNorm software included in the software package qBase Plus from 
Biogazelle (Ghent, Belgium) in order to determine the minimal number of 
reference genes necessary, as well as which genes are the most stable. For 
each primer pair used, a dilution curve in triplicate was established to 
determine amplification efficiency. In cases were all samples could not be fitted 
onto the same plate, inter-run calibrators were used. 
Data was analysed using the qBase Plus software package from Biogazelle 
(Ghent, Belgium). Results are expressed as a ration of the mean expression 
level of the KO compared to the WT. Statistical analysis was done using the 
two-tailed student t-test. Primer sequences are listed in material part 2.1.5. 
 
Table 2.2 qPCR program  
Step Temperature (°C) Time Cycles 
Hot-Start DNA 
Polymerase activation 94 5 mins 1 
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PCR 
Denature        95 15 secs 
40 Anneal/Extend   60 40 secs 
Melt Curve 
95 15 secs 
1 
60 60 secs 
95 15 secs 
 
2.2.7 Reduced Representation Bisulfite Sequencing (RRBS)  
The genome DNA methylation analysis were performed by Zymo Research. 
Libraries were prepared from 20 ng of genomic DNA from HSC, digested with 
60 units of TaqαI and 30 units of MspI (NEB) sequentially and then extracted 
with Zymo Research (ZR) DNA Clean & ConcentratorTM-5 kit (Cat#: D4003). 
Fragments were ligated to pre-annealed adapters containing 
5’-methyl-cytosine instead of cytosine according to Illumina’s specified 
guidelines (www.illumina.com). Adaptor-ligated fragments of 150–250 bp and 
250–350 bp in size were recovered from a 2.5% NuSieve 1:1 agarose gel 
(ZymocleanTM Gel DNA Recovery Kit, ZR Cat#: D4001). The fragments were 
then bisulfite-treated using the EZ DNA Methylation-LightningTM Kit (ZR, Cat#: 
D5020). Preparative-scale PCR was performed and the resulting products 
were purified (DNA Clean & ConcentratorTM - ZR, Cat#D4005) for sequencing 
on an Illumina HiSeq. 
 
Sequence reads from bisulfite-treated EpiQuest libraries were identified using 
standard Illumina base-calling software and then analyzed using a Zymo 
Research proprietary analysis pipeline, which is written in Python and used 
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Bismark (http://www.bioinformatics.babraham.ac.uk/projects/bismark/) to 
perform the alignment. Index files were constructed using the 
bismark_genome_preparation command and the entire reference genome. 
The --non_directional parameter was applied while running Bismark. All other 
parameters were set to default. Filled-in nucleotides were trimmed off when 
doing methylation calling. The methylation level of each sampled cytosine was 
estimated as the number of reads reporting a C, divided by the total number of 
reads reporting a C or T. Fisher’s exact test was performed for each CpG site 
which has at least five reads coverage, and promoter, gene body and CpG 
island annotations were added for each CpG included in the comparison. 
 
2.2.8 Cell treatments 
To evaluate the effects of different cytokines to control and Zeb2-KO 
hematopoietic cells, freshly isolated whole bone marrow cells or purified 
myeloid and Lin- cells were firstly starved in 200μL IMDM medium with 0.5% 
FBS at 37°C for 30 minutes. After starvation, 10ng/ml of IL-3, IL-6, IL-7 or 
G-CSF were added to the cells for 15 minutes. The dilution strategy was listed 
below (Table 2.3). To stop the simulation process, cells for intracellular staining 
were added 200μL of 4% PFA, while cells for western blot were centrifuged 
and lysed with RIPA buffer. The ruxolitinib was preincubated for 15 minutes 
before G-CSF treatment. 
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Table 2.3 Cytokine dilution stragegy 
Cytokines Stock conc. Final conc. Dilution 
IL-3 10ng/ul 10ng/mL 1/1000 
IL-6 10ng/ul 10ng/mL 1/1000 
IL-7 10ng/ul 10ng/mL 1/1000 
G-CSF 600ng/ul 10ng/mL 1/600000 
Ruxolitinib 30mM 80nM 1/375000 
 
2.2.9 Intracellular protein staining 
To detect intracellular phosphorylated proteins, stimulated and control cells 
were fixed with 2% paraformaldehyde at 37°C for 10min. Samples were 
washed with staining buffer and followed by permeabilization with cold BD 
Perm/Wash III reagent. Cells were then frozen at -80°C for 30min or overnight. 
Next, thawed cells were labeled with anti-phospho and surface antibodies. 
FITC-conjugated anti-rabbit secondary antibody was used in the end to detect 
phosphor signal.   
 
2.2.10 Western blot 
Protein preparation 
Protein was extracted from cell lysates by RIPA lysis buffer with 1% of 
phosphorylases inhibitors (Sigma). To quantify the total protein content, BCA 
kit (Pierce) was used. According to the concentration measured by 
spectrophotometer, we were able to calculate the volume containing 30μg 
protein of each sample and diluted it with loading buffer (Pierce). The mixtures 
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were heated at 70°C for 15min to denature the high structure.  
 
Gel electrophoresis 
In this study, NuPAGE 4-12% Bis-Tris Protein Gels (Invitrogen) were used, 
which give optimal separation of small-sized proteins. Two gels were clamped 
in the electrophoresis chamber and the chambers were filled with SDS running 
buffer (Invitrogen). 30μg of denatured proteins were loaded into the gel, 
including 2 lanes with 5μL of molecular weight marker. The gel was then 
connected to the power supply and run at 80V for 30min, followed by 120V, 
until the blue dye reaches the bottom.  
 
Blotting 
Blotting is to immobilize proteins out of the gel and transfer to the membrane 
for immunostaining. Here we use polyvinylidene difluoride (PVDF) membrane, 
which was pre-incubated and activate with methanol. Then the transfer 
sandwich was prepared. A sponge, two whatman filter papers, the gel, the 
PVDF membrane, another two whatman filter papers and a second sponge 
were placed on the black site of the blot cassette, which was then closed and 
placed in the transfer tank, filled with cold transfer buffer. The gels were 
electrotransferred at constant voltage 65V for 1.5 hours at 4°C.   
 
Blocking, staining and developing 
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The membrane was blocked with 5% milk powder in TBS-T buffer for one hour 
at room temperature under gentle agitation. According to the sizes of different 
proteins, we cut the membrane to small pieces and incubate them with primary 
antibodies at 4°C overnight on an orbital shaker. The primary antibodies were 
diluted with 5% BSA in TBS-T buffer. After 4 times of 5 minutes washing with 
TBS-T, horseradish peroxidase (HRP) conjugated secondary antibody was 
added and incubate for 1 hour. Membrane was again washed 3 times for 5min 
with TBS-T. For detecting HRP activity, ECL reagent (equal amount of solution 
A and B, GE Healthcare) was used and generated chemiluminescence was 
measured by ChemiDoc imaging system.  
 
2.2.11 Statistical analyses  
Statistical analysis was done using the unpaired two-tailed student t-test; 
significance was set at p values less than 0.05. The tests were performed 
either with Microsoft Excel or GraphPad Prism. Fisher’s exact test was 
performed for each CpG site which has at least five reads coverage in the 
RRBS assay. 
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3. Results 
3.1 Zeb2 expression in adult murine hematopoietic cells is 
required for terminal erythroid differentiation 
Terminal erythroid differentiation is the process by which nucleated 
proerythroblasts (ProE) mature into enucleated red blood cells (RBCs). ProE 
undergo 3-4 mitotic cell divisions and further generate sequentially basophilic 
erythroblasts (BasoE), polychromatic erythroblasts (PolyE), and 
orthochromatic erythroblasts (OrthoE).  Subsequently, OrthoE exit the cell 
cycle and enucleate to become reticulocytes (Retic), and then mature RBCs 
are developed and circulate in the blood stream. Erythroid terminal 
differentiation is tightly and precisely controlled by differentiation divisions, 
which is highly coupled to the irreversible cell cycle exit. Our previous data 
showed that Zeb2 deletion is embryonic lethal and Zeb2-deficient ES cells 
failed to produce hemoglobin producing erythoid cells  (Goossens et al., 
2011). When Zeb2 was deleted in adult age, mice develop anemia, which was 
progressive over time. So we firstly investigated the erythroid differentiation 
upon Zeb2 ablation.  
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3.1.1 Zeb2-deficiency leads to an impaired terminal 
differentiation of the erythroid lineage 
First we performed peripheral blood analysis at 8 weeks after Poly (I:C) 
administration and evaluated different erythrocyte specific parameters. 
Zeb2Δ/ΔMx1-Cre animals displayed significant reductions of red blood cell counts 
(RBC), hemoglobin (Hb) and hematocrit (HCT) values, but increased level of 
mean corpuscular volume (MCV) than control mice, indicating increased size 
of erythrocytes. The frequency of reticulocytes was analyzed using Thiazole 
orange (TO), which is a nucleic acid binding dye. We detected a two fold 
increase in the percentage of reticulocytes in Zeb2Δ/ΔMx1-Cre mice compared to 
controls (Table 3.1). This data indicate, that in absence of Zeb2 there is an 
augmented erythropoiesis, but it is still not sufficient to compensate and 
balance the number of red blood cells over time.   
 
Table 3.1 Hematologic parameters in control and Zeb2Δ/ΔMx1-Cre mice 
    control Zeb2Δ/ΔMx1-Cre p   
RBC M/uL 10.46±0.54 7.90±0.45 0.003 ** 
HB g/dL 13.52±0.49 11.15±0.56 0.006 ** 
HCT % 45.30±2.19 38.05±2.28 0.037 * 
MCV fL 43.40±0.52 48.09±0.58  <0.001 *** 
MCH Pg 13.08±0.51 14.16±0.46 0.137  
MCHC g/dL 30.14±1.02 29.50±0.89 0.644  
RDW % 18.36±0.60 19.18±0.47 0.307  
Reticulocyte % 2.55±0.11 5.70±1.00 0.040 * 
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To investigate what accounts for the anemia in Zeb2Δ/ΔMx1-Cre mice, bone 
marrow and spleen cells were collected and analyzed using erythroid surface 
markers by flow cytometry. During erythroid maturation, progenitor cells are 
losing CD71 expression while gaining Ter119 markers. We noted that more 
ProE (CD71- Ter119-) and BasoE (CD71+ Ter119+) were accumulated in both 
bone marrow and spleen, while late BasoE and PolyE (CD71med Ter119+) 
and OrthoE (CD71- Ter119+) populations were dramatically reduced, 
compared to values in control animals (Fig. 3.1, 3.2). These data indicate an 
affected differentiation at the transition from early erythroid progenitors to later 
stages of maturation.   
We then investigated the earliest erythroid progenitor burst forming 
unit-erythroid (BFU-E) and more mature colony forming unit-erythroid (CFU-E), 
which gives rise to proerythroblasts. There was no difference in the frequency 
of BFU-E and CFU-E colonies between bone marrow of Zeb2Δ/ΔMx1-Cre and 
controls, while CFU-E cells were increased in spleen after Zeb2 deletion (Fig. 
3.3). These data suggest that the partial differentiation block is not at the stage 
of BFU-E and CFU-E cells, but at the transition from BasoE to PolyE stage of 
differentiation and the increase in CFU-U in spleens of Zeb2Δ/ΔMx1-Cre mice 
might be due to general increase of spleen erythropoiesis in Zeb2-deficient 
mice.  
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Figure 3.1. Representative flow cytometric patterns of erythroid differentiation in vivo. 
Regions I-VI define distinct stages of erythroid differentiation and corresponded to pro E, 
basophilic E, polychromatophilic E, orthochromatophilic E, reticulocyte and mature RBC 
respectively. 
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Figure 3.2 The percentage of indicated erythroid fractions in BM and spleen respectively. 
Data are shown as means ± SEM. *, P< 0.05, **, P < 0.01. 
 
 
Fig 3.3 Erythroid colony-forming counts (BFU-E and CFU-E) from bone marrow and 
spleen cells of control and Zeb2-KO mice. Data are shown as the means ± SE of three 
independent experiments. *, P< 0.05.  
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As we observed increase in reticulocytes, we were wondering whether Zeb2 
deficiency was only affecting steady state erythropoiesis or is also involved in 
stress erythropoiesis. We therefore induced hemolytic anemia by 
phenylhydrazine (PHZ) treatment, which leads to denaturation of erythrocytes 
and results in decreased HCT and increased reticulocytes. After 2 consecutive 
days of PHZ administration, Zeb2-deficient mice displayed a similar recovery 
kinetic in hematocrit, and were able to recover to the initial hematocrit and 
hemoglobin values as the control animals (Fig. 3.4). To exclude the different 
capacity of splenic erythropoiesis between control and Zeb2Δ/ΔMx1-Cre mice, we 
compared responses of transplanted recipients reconstituted with control and 
Zeb2Δ/ΔMx1-Cre donor cells to PHZ challenge. Again, we did not observe a 
significant difference in the kinetic of recovery between control and 
Zeb2Δ/ΔMx1-Cre bone marrow recipients (Fig. 3.4 bottom panel). Since the steady 
state erythropoiesis is mainly restricted to the bone marrow, while adult spleen 
is the primary effector to stress erythropoiesis (Paulson et al., 2011), our data 
suggest that Zeb2 is mainly involved in steady state erythropoiesis, while it is 
dispensable stress erythropoiesis.  
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Figure 3.4 Hematocrit and reticulocyte assessments in the steady-state (upper) and 
control and Zeb2-KO hematopoietic cells transplanted mice (bottom) after induction of 
hemolytic anemia with PHZ. Data are shown as means ± SEM. *, P< 0.05, **, P < 0.01; ***, 
P < 0.001. 
 
3.1.2 Impaired erythropoiesis in Zeb2 deletion mice is due to a 
primary intrinsic defect 
To test whether defects in erythropoiesis in Zeb2Δ/ΔMx1-Cre mice are caused by 
an intrinsic effect of marrow cells themselves or are influenced by the affected 
microenvironment, a bone marrow transplant was performed. The peripheral 
blood from recipients was collected and analyzed 4, 8, 12, 16 weeks 
post-transplantation. A consistent but more pronounced anemia was observed 
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in recipients with Zeb2Δ/ΔMx1-Cre donor cells throughout the course of 
engraftment (Fig. 3.5), recapitulating the phenotype of donor mice. To further 
exclude a possible nice effect we performed an additional niche transplant 
assay by transplanting wild type bone marrow cells (CD45.2) into lethally 
irradiated control and Zeb2Δ/ΔMx1-Cre (CD45.1) recipients. After 16 weeks, both 
recipient groups did not display abnormal parameters in the erythroid lineage 
(Fig. 3.6). This data confirms that the abnormalities are intrinsic to the marrow 
cells themselves and independent from bone marrow microenvironment. 
 
 
Figure 3.5 Assessment of RBC, hemaglobin (Hb), hematocrit (HCT) and 
mean corpuscular volume (MCV) in peripheral blood 4, 8, 12 and 16 weeks 
posttransplantation. Data are shown as means ± SEM. *, P< 0.05, **, P < 0.01; ***, P < 
0.001. 
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Figure 3.6 Analysis of donor cells repopulation and reconstitution in peripheral blood 16w 
after niche transplant. Data are shown as means ± SEM. *, P< 0.05, **, P < 0.01; ***, P < 
0.001. 
 
3.1.3 Zeb2 does not affect cell cycle activity but impact the 
expression of key transcription factors in erythroid 
progenitors 
Since the terminal erythroid differentiation is tightly associated with cell cycle, 
we next thought to investigate whether cell cycle defects are responsible for 
the differentiation block in Zeb2Δ/ΔMx1-Cre mice. The cell cycle analysis in 
different erythroid subsets of BM compartment by Ki67 detection revealed that 
the distribution of cells in quiescent (G0), growth (G1), and cell cycle (S/G2/M) 
phases had no difference between Zeb2Δ/ΔMx1-Cre and control mice. However, 
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when we analyzed the erythroid subsets in the spleens there was significant 
decrease in proportions of BasoE and PolyE cells that were in G0 status of the 
cell cycle, while increase in dividing cells (S/G2/M phases) in Zeb2-KO mice 
compared to controls (Fig. 3.7). Furthermore, in vivo BrdU incorporation assay 
was performed by giving Zeb2Δ/ΔMx1-Cre and littermate controls a single injection 
of BrdU, which can detect new DNA synthesis. Mice were sacrificed and 
analyzed 1h later. Consistent with Ki67 analysis, the data did not show 
different cell cycle distribution of erythroid population in the BM between 
control and Zeb2Δ/ΔMx1-Cre mice. Although we observed a similar trend in BrdU 
incorporation in the spleens, these were not statistically significant (Fig. 3.7). 
These data indicated that Zeb2 has no effect on cell cycle activity in bone 
marrow erythroid cells. However, there is accelerated proliferation in erythroid 
cells from Zeb2Δ/ΔMx1-Cre spleen, which may be responsible for constant stress 
hematopoiesis due to anemia caused by insufficient bone marrow 
erythropoiesis and contribute to increased reticulocyte number.  
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Figure 3.7 Cell cycle analysis by Ki-67 assays. Data show the distribution of indicated 
erythroid subsets in BM and spleen from control and Zeb2
Δ/ΔMx1-Cre
. Data are shown as 
means ± SEM. *, P< 0.05, **, P < 0.01; ***, P < 0.001. 
 
 
Figure 3.8 Cell cycle analysis by BrdU incorporation assay. Data show the distribution of 
indicated erythroid subsets in BM and spleen from control and Zeb2
Δ/ΔMx1-Cre
. Data are 
shown as means ± SEM.  
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We next examined the expression of putative transcription factors that 
contribute to erythropoiesis in sorted CD71highTER119+/- population from BM of 
Zeb2Δ/ΔMx1-Cre and control mice by real-time PCR analysis. The result showed 
that Zeb2 loss led to downregulation of Gata1, Fli2 and Klf2, which are mostly 
associated with erythroid differentiation. The balance between Klf1 and Fli1 
plays an antagonistic role in the regulation of erythroid versus megakaryocyte 
development. Our previous data also indicated that in the absence of Zeb2, 
megakaryocytes are developing but show maturation impairment at the stage 
of terminal differentiation. In conclusion, the dysregulation of Klf1 and Fli1, as 
well as Gata1 in Zeb2-deficient early erythroid progenitors, may be due to 
dysregulation of key transcription factors that are promoting terminal 
differentiation in the erythroid lineage.   
 
Figure 3.9 Potential target genes of Zeb2 in erythropoiesis. Folds change of mRNA levels 
(Zeb2
Δ/ΔMx1-Cre
 over controls) of indicated genes in sorted CD71highTER119+/- population. 
Data are shown as mean ± SEM. *, P< 0.05, **, P < 0.01; ***, P < 0.001. 
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3.2 Zeb2 is essential for B-cell differentiation and 
orchestrates the transcriptional network by epigenetic 
regulation 
The hierarchical network of transcription factors and epigenetic regulators 
mediate different stages of B-cell development, which starts from 
lymphoid-primed multipotent progenitors (LMPPs). LMPPs give rise to 
common lymphoid progenitors (CLPs), which further differentiate into early 
B-cell precursors: Prepro-B, Pro-B and Pre-B cells, and terminally 
differentiated mature B cells. Our previous data showed significantly lower 
number of B-lymphocytes in both peripheral blood (less than 20% of control) 
and bone marrow (5% of control) after Zeb2 deletion. However, at which stage 
of differentiation B lineage exhibited a differentiation block was not clear. 
 
3.2.1 Loss of Zeb2 results in arrested B-cell development at 
Prepro-B stage 
We first investigated different stages of B-cell maturation in the bone marrow of 
WT and Zeb2Δ/ΔMx1-Cre animals based on surface marker expression profile 
using flow cytometry. Deletion of Zeb2 in the hematopoietic system did not 
change the relative frequency of LMPPs within the LKS compartment (Fig. 
3.10). However, due to increased number of LKS in the BM, the absolute cell 
numbers of LMPPs were significantly increased in the BM of Zeb2-deficient 
59 
 
mice compared with littermate controls (Fig. 3.10). CLPs were found at similar 
frequency in the BM of Zeb2Δ/ΔMx1-Cre and controls. Those data demonstrated 
that impaired B-cell differentiation in mice which lacking Zeb2 were not due to 
impaired lymphoid lineage commitment.  
 
 
Figure 3.10 FACS analysis of whole bone marrow cells to detect lymphoid-primed 
multipotent progenitors (LMPPs) and common lymphoid progenitors (CLPs) in control and 
Zeb2
Δ/ΔMx1-Cre
, as the gating strategy indicated. LMPPs are characterized by their LKS 
(Lineage
-
 c-Kit
+
 Sca-1
+)
 Flt-3+ surface marker phenotype, while CLP (c-Kit
med
 Sca-1
med
) 
were gated from Lineage-, CD127+ compartment.  
 
We further analyzed specified B-cell subsets from B220+ compartment. 
Prepro-B is recognized as the first specified B-cell precursor and can 
developmentally progress to progenitor B-cells (Pro-B and Pre-B). All these 
three populations could be identified from B220+IgM-IgD- population by the 
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determination of c-Kit and CD24 expression (Fig. 3.11). The analyses revealed 
that Zeb2-deficient cells exhibited an apparent accumulation of Prepro-B but 
massively diminished Pro-B and Pre-B population. However, other late stages 
of B-cell subpopulations showed similar relative frequencies within the B220+ 
BM cells in both genotypes.  
 
 
Figure 3.11 Representative immunophenotypic analysis of B220+ B lymphocytes in 
control and Zeb2
Δ/ΔMx1-Cre
 mice. The IgM
-
IgD
-
 cells in the B220
+
 were gated out for 
Pre-Pro-B cell analysis. Curved arrow represents the B-cell differentiation transition from 
immature- to mature-B cells. A: Immature B; B: Transitional B; C: early mature B (Marginal 
Zone B and Regulatory B); D: late mature B (Follicular B, Germinal-Center B and plasma 
B).  
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In order to confirm the differentiation block at the transition from Prepro-B to 
Pro-B in Zeb2-deficient BM cells, we examined B-cell subsets by an additional 
panel, which is based on CD19 and CD 24 expression. CD19 is a cell surface 
antigen that is broadly expressed beginning at the Pro-B cells until mature B 
cells, which allowed us define the Prepro-B population. As depicted in a 
representative FACS plot, a notable differentiation block at the transition from 
Prepro-B to Pro-B stage was observed after Zeb2 deletion (Fig. 3.12).  
 
 
Figure 3.12 Representative staining profiles for Prepro-B (B220
+
IgM
-
CD19
-
CD43
+
), Pro-B 
(B220
+
IgM
-
CD19
+
CD43
+
), Pre- and immature B (B220
+
IgM
-
CD19
+
CD43
-
), and mature B 
(B220
+
IgM
+
) fractions in the BM of Zeb2
Δ/ΔMx1-Cre
 mice and controls.  
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The statistical analyses of at least 3 biological replicates calculating different 
B-cell subsets within B220+ bone marrow population further supported the 
developmental block at Prepro-B stage (38% in B220+ in Zeb2-deficient mice 
compared to 6% in controls) (Fig. 3.13). This data indicate that Zeb2 is 
essential for specification of B-cell development. However, since at later 
stages no significant relative differences between more mature B-cell subsets 
were detectable, we conclude that Zeb2 is not required for later stages of 
differentiation or maintenance.  
 
 
Figure 3.13 B-subsets distribution in control and Zeb2-deficienct cells. Shown are the 
percentages of indicated B fractions (based on the CD19 staining) in BM and B220 
respectively. Data are shown as means ± SEM. *, P< 0.05, **, P < 0.01; ***, P < 0.001.  
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3.2.2 Zeb2-deficiency leads to impaired IL-7 receptor signaling 
and transcriptional network in Prepro-B 
B-lymphopoiesis is precisely controlled by hierarchical network of key 
transcription factors. We analyzed mRNA expression of B-specific regulators in 
sorted Prepro-B population, in which the differentiation block was asserted. We 
found numerous genes to be down regulated upon Zeb2 deletion, including 
IL-7R, and its target EBF and Pax5 (Fig. 3.14). In addition, we found some key 
regulators of early B-cell development upregulated in Prepro-B cells, like E2A 
(1.8-fold increase), PU.1 (1.9-fold increase), Runx1 (1.4-fold increase), and Id2 
(2.6-fold increase), while Id3 was strikingly inhibited. 
  
 
Figure 3.14 Potential target genes of Zeb2 in B-cell development. Folds change of mRNA 
levels (Zeb2
Δ/ΔMx1-Cre
 over controls) of indicated genes. Data are shown as mean ± SEM. *, 
P< 0.05, **, P < 0.01; ***, P < 0.001. 
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It has been suggested that IL-7 receptor signaling pathway can stimulate B-cell 
differentiation through up-regulation of Ebf and its target genes (Kikuchi et al., 
2005). IL-7Rα-/- mice displayed a similar B differentiation block at Prepro-B 
stage as we observed in Zeb2 deficient mice. It is known that STAT5 could be 
activated by IL-7 signaling, so we further evaluated the phosphorylation of 
STAT5 in Prepro-B cells in response to IL-7 administration. Upon stimulating 
BM cells with 20ng/ml recombinant murine IL-7 for 15 min, the expression level 
of activated pSTAT5 was highly increased in WT Prepro-B cells, however, no 
detectable response was observed in corresponding Zeb2 deficient cells (Fig. 
3.15). Thus, in the absence of Zeb2, early B-cell progenitors do not respond to 
IL-7 signaling, most likely due to lack of corresponding receptor expression. 
This may contribute to an impaired transcription factor network that is initiated 
upon IL7 signaling in Prepro-B cell subset.   
 
Fig. 3.15 Flow cytometry analysis of intracellular phosphorylated STAT5 in Prepro-B-cell 
population of Zeb2
Δ/ΔMx1-Cre
 mice and controls. BM cells were stimulated (blue line) or not 
stimulated (red line) with IL-7 for 15 min. Prepro-B population has been gated on 
B220
+
IgM
-
CD19
-
CD43
+
 subset.  
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3.2.3 Zeb2 loss results in altered epigenetic regulation  
In recent years, investigators have shown that epigenetic regulator- 
transcription factor complexes play critical roles during B-cell development. It 
has been demonstrated previously, that Zeb2 can affect gene expression by its 
ability to bind to the NuRD corepressor complex (Verstappen et al., 2008). To 
further investigate whether Zeb2 affects the expression level of key members 
of the nucleosome remodeling machinery, we performed qPCR analyses on 
sorted Prepro-B subset. We found 1.9 folds increase in Ezh2 and 1.7 folds 
increase in Suz12 expression, which are crucial members of the polycomb 
repressive complex 2 (PRC-2). PRC-2 is involved in histone modification, 
specifically in methylation of the lysine residue at the position 27 of the Histone 
3 (H3K27). In addition, we found a slight but significant increase in mRNA 
expression in Lsd1 and Mi-2β, the components of the Mi-2/NuRD complex, 
while no difference in the expression level of HDACs were detectable (Fig. 
3.16).  
 
 
Fig. 3.16. Relative expression levels of selected PRC-2 and Mi-2/NuRD components 
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measured by real-time PCR analysis. Values are in Zeb2
Δ/ΔMx1-Cre
 Prepro-B cells 
normalized to the expression levels in controls. Data are shown as mean ± SEM. *, P< 
0.05, **, P < 0.01; ***, P < 0.001. 
 
Histone acetylation and methylation are the best characterized epigenetic 
modifications. Lysine residues of histone 3 can be mono-, di-, or tri-methylated, 
each of which can differentially regulate chromatin structure and modulate 
transcription. In general, acetylation at H3K9, H3K14 and H3K18, or 
tri-methylation at H3K4, H3K36 and H3K79 are associated with open 
chromatin structure and considered as activating histone marks, whereas 
tri-methylation at H3K9 and H3K27 have been characterized as repression 
marks. In order to investigate whether altered histone remodeling complexes 
will lead to changed expression levels of different H3 modifications in 
Zeb2Δ/ΔMx1-Cre cells, we next quantified 21 of H3 modifiers by colorimetric 
based ELISA-like assay. B220low population, which is enriched with early B-cell 
subsets, was sorted for the measurement instead of Prepro-B population, 
since a certain amount of histone protein were needed. Strikingly, the majority 
of the H3 modification levels was elevated in absence of Zeb2, including 
H3K4me3 and H3K27me3, which is consistent with higher expression level of 
PRC-2 and Mi-2/NuRD complexes. However, when we analyzed whole bone 
marrow (WBM) cells of Zeb2-deficient and control mice only little differences 
were detected between the genotypes, implicating that the differences were 
only in cells with block in differentiation and diluted by other hematopoietic 
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lineages, like granulocytes, wich is the largest bone marrow population (Fig. 
3.17). In summary, loss of Zeb2 can cause altered histone modification, which 
is cell population specific.  
 
 
Fig 3.17 Relative change of each histone H3 modification between Zeb2
Δ/ΔMx1-Cre
 and 
control WBM (top) and B220
low
 cells (bottom). Values were normalized to total H3 
expression level 
 
It has been demonstrated that histone modification and DNA methylation can 
influence or be dependent on each other. A recent study of Dnmt3a-null HSCs 
identified some increased HSC fingerprint genes without decreased 
methylation level, but within increased H3K4me3 expression level, this 
suggests two distinct mechanisms being involved in the upregulation of HSC 
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genes in Dnmt3a-null HSCs: hypomethylating directly binding targets (Runx1 
and Gata3), and indirect histone modifications (Nr4a2) (Challen et al., 2012). 
Since Runx1, Gata3 and PU.1 are all significantly altered in their expression 
upon Zeb2 deletion as well, we next examined the mRNA levels of DNA 
methyltransferases (Dnmt1, Dnmt3a and Dnmt3b) and Tet methylcytosine 
dioxygenases (Tet1, Tet2 and Tet3) in sorted Prepro-B cells by real-time PCR. 
We found that Dnmt1 and Dnmt3b had 2.3- and 1.4-fold increase respectively, 
but Dnmt3a was slightly decreased, while all three Tets were consistently down 
regulated after Zeb2 deletion (Fig. 3.18). Thus, the impaired transcription 
factor network in Prepro-B population may be caused by altered epigenetic 
regulation mechanisms, including histone modification and DNA methylation. 
  
 
Figure 3.18 Relative expression levels of selected genes measured by real-time PCR 
analysis. Values are in sorted Zeb2
Δ/ΔMx1-Cre
 Prepro-B cells normalized to the expression 
levels in controls. Data are shown as mean ± SEM. *, P< 0.05, **, P < 0.01; ***, P < 0.001. 
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3.2.4 Zeb2 is affecting the transcriptional and epigenetic 
programs also at the stem- and progenitor level 
It has been demonstrated that epigenetic marks play a pivotal role in HSC 
development and orchestrate the fate decision between stemness and lineage 
commitment. The link between the abnormal epigenetic code and B-cell 
differentiation failure upon Zeb2 deletion gave us a hint to hypothesize that 
defective epigenetic marks may take place in progenitor or even stem cell 
population of Zeb2-deficient mice. If so, this may provide an explanation for the 
complex Zeb2Δ/ΔMx1-Cre phenotype.  
 
In order to challenge this hypothesis, we examined the expression levels of 
proteins involved in epigenetic regulation in HSPC population (LKS) by 
real-time PCR. Consistent with the major differences, we observed in Prepro-B 
cells, Eed and Ezh2 of PRC2 complex were highly upregulated in 
Zeb2-deficient LKS cells, whereas analyses of different components of the 
Mi-2/NuRD complex revealed only a significant upregulation of LSD1. In 
addition, Zeb2Δ/ΔMx1-Cre LKS cells showed higher expression of three DNA 
methyltransferases Dnmt-1 (2-fold), Dnmt-3a (2.1-fold) and Dnmt-3b (2-fold), 
while no difference in the expression level of Tet methylcytosine dioxygenases 
was detectable (Fig. 3.19). Taken together, the observed changes in 
expression for epigenetic factors, mainly Dnmts, in LKS cells may be 
responsible or contribute to the phenotype in Zeb2-deficient hematopoiesis.    
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Figure 3.19 Relative expression levels of epigenetic factors measured by real-time PCR 
analysis. Values are in sorted Zeb2
Δ/ΔMx1-Cre
 LKS (Lin
-
Sca-1
+
c-Kit
+
) cells normalized to the 
expression levels in controls. Data are shown as mean ± SEM. *, P< 0.05, **, P < 0.01; ***, 
P < 0.001. 
 
We next wondered if changes in expression of epigenetic regulators affect the 
expression of key multipotency and differentiation transcription factors in LKS 
population. We found an upregulation of Runx1 (2.1-fold increase) and Gata-2 
(2.1-fold increase) in Zeb2-deficient LKS cells, which is known to be essential 
for preservation of stemness and thus might contribute to differentiation 
inhibition. On the other hand we saw an overexpression of PU.1 (1.5-fold 
increase) and E2A (1.7-fold increase), which might lead to impaired B-lineage 
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commitment (Fig. 3.20). It has been reported that Dnmt3a-null HSCs could 
upregulate HSC multipotency factors (including Runx-1 and Foxo-1) and inhibit 
differentiation genes (including PU.1 and E2A) through affecting the DNA 
methylation level (Challen et al., 2012). As Zeb2 deficient cells display 
increased expression of PU.1 and E2A, and we observe an increase in the 
expression level of these genes supports our hypothesis, that Zeb2 may act by 
modifying DNA methylation. This indicated that the changes observed in 
Zeb2-deficient LKS cells would probably be caused by a broad spectrum of 
epigenetic changes, mainly via changed DNA methylation.  
 
 
Figure 3.20 Relative expression levels of select key multipotency and differentiation genes 
measured by real-time PCR analysis. Values are in Zeb2
Δ/ΔMx1-Cre
 LKS cells normalized to 
the expression levels in controls. Data are shown as mean ± SEM. *, P< 0.05, **, P < 0.01. 
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3.2.5 Zeb2 loss in HSCs leads to perturbed DNA methylation  
To investigate the impact of Zeb2 on DNA methylation, we performed 
genome-wide RRBS analysis, which enables quantitative DNA methylation 
measurements using low amount of genomic DNA and therefore enabling to 
perform this assay within a relatively small population like HSC. Thus, 
LKS-SLAM (LKS CD48-CD150+) populations were sorted from Zeb2Δ/ΔMx1-Cre 
and control mice, and two biological replicates for each genotype were 
analyzed. In the RRBS analysis, 4.4 million CpG sites were covered with 
average 16X and 28X CpG coverage in control and Zeb2Δ/ΔMx1-Cre samples 
respectively (Table 3.2). About 95% of CpG islands (CGIs), 85% of gene 
bodies and 75% of promoters had more than 10 fold read coverage. This 
coverage and read depth allowed a confident examination of differential 
genomic methylation patterns (Figure 3.21). In mammals, 70% to 80% of CpG 
cytosines are methylated, however only very rare within CpG islands (Jabbari 
and Bernardi, 2004). Comparison of global CpG methylation levels within 
promoter, gene body and CpG islands between WT and Zeb2Δ/ΔMx1-Cre HSCs 
showed no difference in the whole genome (Fig. 3.22).  
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Table 3.2 Statistics of RRBS analysis. 
Sample 
Total Read 
Number 
Mapping 
Efficiency 
Unique CpGs 
Avg. CpG 
Coverage 
Bisulfite 
Conversion Rate 
Control 1 68,803,864  35% 6,012,631 16X 99% 
Control 2 55,447,891  52% 6,263,200 18X 99% 
Zeb2-KO 1 76,628,398  57% 6,567,027 28X 99% 
Zeb2-KO 2 79,461,656  57% 6,383,905 30X 99% 
 
 
Figure 3.21 RRBS read coverage at the promoter, gene body and CpG islands.  
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Figure 3.22 Comparison of global CpG methylation levels within promoter, gene body and 
CpG islands between Zeb2 WT and KO HSCs. The boxplot displays the mean DNA 
methylation levels as well as the distribution of methylation levels within a sample. The 
boxplots show the 2nd quartile (mean) as a yellow line, and 1st quartile and 3rd quartile as 
the bottom and upper bounds of the box, respectively. 
 
To gain further insight into the similarities and differences in DNA methylation 
between WT and Zeb2 KO, we analyzed methylation changes at individual 
CpG site. We found that 5% of covered CpGs were differentially methylated 
between WT and Zeb2Δ/ΔMx1-Cre HSC. Upon Zeb2 ablation, 72% of these 
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differentially methylated cites exhibited an increased methylation and 28% of 
which exhibited increase (hyper) and decreased (hypo) in methylation at the 
CpG cited compared to WT respectively (Table 3.3, Fig. 3.23).   
 
Table 3.3 The counts of CpG sites in differential methylation 
Classification of CpG sites  Count  
insignificant 4195646  
strongly hypermethylated 12633  
hypermethylated 133578  
strongly hypomethylated 5320  
hypomethylated 52518  
Hypermethylated: 0-33% more methylated than reference (p-value < 0.05); 
hypomethylated: 0-33% less methylated than reference (p-value < 0.05); strongly 
hypermethylated: 33-100% more methylated than reference (p-value < 0.05); strongly 
hypomethylated: 33-100% less methylated than reference (p-value < 0.05); insignificant: 
statistically insignificant difference in methylation. 
 
 
Figure 3.23 Scatter plots depict correlation between WT and Zeb2 KO. Blue dots show 
sites with statistically insignificant differences between samples, significantly hypo- or 
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hyper-methylated sites are colored yellow or green respectively. The orange and blue 
triangle area indicates 33‐100% less and more methylated Zeb2 KO HSCs than control 
HSCs. 
 
Although the overall DNA methylation changes did not differ greatly between 
Zeb2-deficient and control HSC, there may be specific sites where changes in 
methylation are biologically important. We therefore examined the CpGs of key 
HSC regulators, according to our previous qRT-PCR analysis, which were 
differentially expressed between WT and Zeb2Δ/ΔMx1-Cre in LKS as well as 
Prepro-B population. Interestingly, some of those genes that we identified 
previously to be differentially expressed also showed changes in methylation, 
including PU.1, Foxo-1, Pax5 and ID-3. Moreover, additional genes with higher 
or lower methylation have been identified, which are also associated with stem 
cell fingerprint, such as Lmo2, Pbx1, Prdm16 and Runx3 (Fig. 3.24). The 
changes in methylation was also translated in changes in gene expression, as 
examined by real-time PCR (Fig. 3.25).   
 
 
Figure 3.24 UCSC genome browser track of hypermethylated Runx3 fragment. 
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Chr4:135,175,598-135,175,602, 5 bp, in both WT and Zeb2 KO were displayed and the 
methylation ratios at each site were indicated. The label on the left of a CpG, say ‘17/21’, 
indicates 17 reads were methylated in 21–fold sequencing read coverage and the DNA 
methlation ratio was 81%. Yellow corresponds to higher methylation levels, while red 
corresponds to lower methylation levels. Intermediate methylation levels are represented 
with orange. 
 
 
Figure 3.25 Relative expression levels of select HSC fingerprint genes containing hyper- 
or hypo-methylated CpG sites in LKS population. Values are in Zeb2
Δ/ΔMx1-Cre
 LKS cells 
normalized to the expression levels in controls. Data are shown as mean ± SEM. *, P< 
0.05, **, P < 0.01; ***, P < 0.001. 
 
In conclusion, Zeb2 is essential for multilineage differentiation at different 
stages of hematopoiesis. The differentiation defects observed in Zeb2Δ/ΔMx1-Cre 
mice are at least in part due to changes in DNA methylation of key HSCs 
regulators.  
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3.3 Myeloproliferative disorder upon Zeb2 loss is due to 
altered JAK/STAT signaling pathway 
3.3.1 Zeb2 deficiency results in impaired JAK/STAT signaling 
pathway 
To further characterize the main biological process targeted by Zeb2, gene 
ontology (GO) enrichment analysis was performed over 2,500 genes 
containing strongly hyper- or hypomethylated CpG sites. The results showed 
that genes involved in regulation of cell adhesion, transcription and protein 
kinase (including phosphorylation, serine/threonine protein kinase, tyrosine 
protein kinase) are the most enriched GO terms (Fig. 3.26). As an EMT 
regulator and transcriptional repressor, it is not surprising that altered cell 
adhesion and transcriptional regulation were altered after Zeb2 deletion. 
Interestingly, the GO term associated with protein kinase, in particular tyrosine 
kinase activity was highly enriched as well, which led us to investigate cell 
signaling activity in Zeb2 deficient cells.  
Our previous work showed that upon induction of Zeb2 deficiency within the 
hematopoietic system we observed reduced erythrocytes and thrombocytes 
while granulocytes were increasing over time. In addition these mice 
developed a significant and progressive increase in spleen size. Histological 
analyses revealed a massive destruction of spleen architecture and a massive 
extramedullary hematopoiesis in Zeb2 depleted animals. Silver staining of 
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bone marrow sections showed a significant increase in the appearance of 
reticular fibers in Zeb2Δ/ΔMx1-Cre animals. In addition, there was an increase in 
frequency of megakaryocytes with abnormal morphology in the bone marrow 
and spleen. All above features have been described as a hallmark of 
myeloproliferative diseases in humans (Lang et al., 2003).  
 
 Figure 3.26. GO analysis of the differentially methylated genes.  
 
In 2005, several groups identified a constitutively active JAK2V617F mutation 
in Janus kinase 2 (Jak2) gene in (Ph)-negative MPN bone marrow cells (Klarl 
et al., 2006). This mutation results in constitutively activation of Jak2 and 
subsequently activates signal transducer and activator of transcription (STAT), 
mitogen-activated protein kinase (MAPK)/extracellular signal regulated kinase 
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(ERK) and phosphotidylinositide 3-kinase/protein kinase B-AKT (PI3K/AKT) 
signalling pathways resulting in expansion of the myeloid lineage within the 
bone marrow. More Jak2 mutations that contribute to activation of JAK 
signaling have been discovered in MNPs, which suggests a critical role of JAK 
kinase activity in myeloproliferative disorders (Bratosin et al., 2004). Since 
Zeb2 deficient mice exhibit features resembling MPN in humans, we examined 
the activity of those signaling pathways in the bone marrow from control and 
Zeb2Δ/ΔMx1-Cre mice by intracellular detection of phosphorylated signaling 
proteins utilizing flow cytometry. However, when we analyzed the signaling 
activity at freshly isolated bone marrow cells, we did not detect differences in 
the level of phosphorylated STAT3, STAT5, ERK1/2 between the genotypes at 
steady state (Fig. 3.27).  
Next we sought to test, whether we would observe different sensitivity of the 
signaling pathways, when cells were treated with defined cytokines. To 
investigate the complex network of cytokine/ growth factor in control and 
Zeb2Δ/ΔMx1-Cre hematopoietic system, we harvested the whole bone marrow 
cells and analyzed the activity of JAK/STAT, MAPK/ERK and PI3K/AKT 
signaling by western blot after stimulation with different cytokines. Interestingly, 
Zeb2 deficient bone marrow cells were more sensitive to the granulocyte 
colony- stimulating factor (G-CSF), resulting in striking increase in 
phosphorylation of STAT3, STAT5 and ERK compared to control cells (Fig. 
3.28). In contrast, Zeb2Δ/ΔMx1-Cre cells did not activate the JAK/STAT signaling 
81 
 
pathway neither by IL-3 nor IL-6 stimulation, as no change of phosphorylated 
STATs was detected (Fig. 3.28). However, analyses of p38 and AKT 
phosphorylation upon stimulation with G-CSF, IL3 and IL6 did not show 
difference in activation of these pathways between WT and Zeb2Δ/ΔMx1-Cre bone 
marrow cells (Fig. 3.28).  
 
 
Figure 3.27 Representative flow cytometry analysis of intracellular phosphorylated STAT3, 
STAT5 and ERK in indicated populations.  
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Figure 3.28 Representative western blot showing phosphorylation of STAT3, STAT5, 
ERK1/2, AKT and p38 in total lysates of bone marrow cells from control and Zeb2-KO 
mice in the presence of IL-3 (10ng/ul), IL-6 (10ng/ul) and G-CSF (10ug/ul) for 15 minutes. 
Non-phosphorylated antibodies were used as loading control. 
 
Since bone marrow is containing various hematopoietic lineages, the 
increased activation of STATs in Zeb2Δ/ΔMx1-Cre BM cells after G-CSF 
stimulation might be due to significant increase in the granulocytic lineages 
compared to control mice. Thus we performed western blot analyzes in 
selected Mac1 positive myeloid cells and Lineage negative cells, that contain 
mostly stem and progenitor cells. Consistent with our previous observation in 
total bone marrow cells we observed augmented STAT phosphorylation upon 
G-SCF exposure and diminished or absent signaling upon IL6 stimulation in 
Zeb2Δ/ΔMx1-Cre cell subsets (Fig. 3.29, 3.30). In addition, intracellular 
phosphorylation levels in different hematopoietic lineages were detected by 
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flow cytometry, as this method allows the detection of signaling activity at the 
single cell level. As shown in Fig. 3.31 we not only confirmed our previous 
findings, but also demonstrated that attenuated STAT3 phosphorylation after 
IL-6 stimulation takes place in progenitor cells, which might be responsible for 
impaired differentiation in multiple hematopoietic lineages (Fig. 3.31). 
 
 
Figure 3.29 Representative western blot showing STATs phosphorylation MACS purified 
myeloid cells from control and Zeb2-KO mice in the presence of IL-6 (10ng/ul) and G-CSF 
(10ug/ul) for 15 minutes.  
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Figure 3.30 Representative western blot showing phosphorylation of Stat3 in MACS 
purified Lin- cells from control and Zeb2-KO mice in the presence of IL-6 (10ng/ul) and 
G-CSF for 15 minutes.  
 
 
Figure 3.31 Representative flow cytometry analysis of intracellular phosphorylated STAT3 
in control and Zeb2-KO myeloid and progenitor populations after IL-6 stimulation.  
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Differential activation of JAK/STAT in control and Zeb2-deficient cells 
stimulated by IL-3, IL-6 and G-CSF might be ascribed to differently expressed 
receptors on those cells. Therefore, we examined the expression levels of 
receptors for different cytokines in different populations. Interestingly, IL-6Rα 
was significantly downregulated (0.5-fold) in both progenitors and myeloid cells, 
while the mRNA of G-CSFR and IL-3Rα only decreased in progenitors but not 
in myeloid populations (Fig 3.32). This suggested that the inability of 
Zeb2Δ/ΔMx1-Cre cells facilitating JAK/STAT pathway by IL-6 may due to the 
reduced abundance of its receptors at the cell surface. In contrast, differential 
activation of JAK/STAT to IL-3 and G-CSF in control and Zeb-KO cells might 
be due to other receptor-independent mechanisms.     
 
 
Figure 3.32 Relative expression levels of receptors to G-CSF, IL-3 and IL-6 measured by 
real-time PCR analysis. Values are in Zeb2
Δ/ΔMx1-Cre
 progenitor and myloid cells 
normalized to the expression levels in controls. Data are shown as mean ± SEM. *, P< 
0.05, **, P < 0.01; ***, P < 0.001. 
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3.3.2 JAK inhibition by Ruxolitinib ameliorates some 
myeloproliferative features 
Ruxolitinib is a drug, which is used for the treatment of MPN, related symptoms 
in patients with primary or secondary myelofibrosis. Ruxolitinib is a small 
molecule that selectively inhibits JAK1 and JAK2 kinases (Quintas-Cardama et 
al., 2010). Because Zeb2Δ/ΔMx1-Cre mice exihibit MPN phenotype and 
hematopoietic cells are hypersensitive to G-CSF, we next evaluated the effect 
of ruxolitinib in Zeb2-deficient mice. Firstly, western blot analyses confirmed 
that ruxolitinib was able to abrogate G-CSF-induced activation of JAK/STAT 
pathway in vitro (Fig. 3.33).  
 
 
Figure 3.33 Representative western blot showing phosphorylation of STAT3 and STAT5 in 
total lysates of bone marrow cells from control and Zeb2-KO mice in the presence of only 
G-CSF (10ug/ul) or pretreated cells with ruxolitinib followed by G-CSF stimulation for 15 
minutes.   
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Ruxolitinib was then evaluated in in vivo assays by administration to control 
and Zeb2-KO mice twice a day with either ruxolitinib or vehicle via oral gavage. 
Mice were sacrificed and analyzed one week later. As we expected, Zeb2-KO 
mice, which receiving ruxolitinib, exhibited a significant shrinkage of the spleen, 
but not control mice (Fig. 3.34). However, we did not observe any rescue in 
differentiation of other lineages in Zeb2Δ/ΔMx1-Cre mice (data not shown).  
 
 
Figure 3.34 Representative spleen images of Ctrl and Zeb2
Δ/ΔMx1-Cre
  mice at 1w (top) 
after ruxolitinib or mock administration via oral gavage. The statistical data (bottom) in KO 
mice are shown as mean ± SEM. *, P< 0.05. 
 
In summary, Zeb2 ablation in the hematopoietic compartment led to a 
phenotype with several features reminiscent of myeloproliferative disorders in 
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humans, such as bone marrow fibrosis, splenomegaly and extramedullary 
hematopoiesis. These features may partly be attributed to hypersensitivity of 
the JAK/STAT signaling pathway to selected cytokines, such as G-CSF. While 
retarded activation of JAK/STAT by IL-3 and IL-6 stimulation might be 
responsible for distinct differentiation defects in other hematopoietic lineages 
in Zeb2-deficient mice. 
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4. Discussion 
4.1 The role of Zeb2 in terminal differentiation 
It has been described previously that deletion of Zeb2 within hematopoietic 
compartment results in early embryonic lethality due to differentiation and 
migration defects of fetal liver hematopoietic cells (Goossens et al., 2011). In 
this study, we used the interferon sensitive Mx1-Cre based inducible knockout 
model to generate Zeb2 deficient mice, in which Zeb2 was deleted in adult 
hematopoietic cells upon Poly (I:C) administration. In the first part of the study 
we showed that the transcriptional repressor Zeb2 is important for adult 
erythropoiesis. After Zeb2 allele deletion, mice exhibited progressive anemia 
over time. If the same amount of BM and spleen cells were plated in 
methylcellulose medium, we were not able to detect abnormal number of 
colonies derived from BFU-E or CFU-E in BM, but accumulative CFU-E from 
spleen. This is most likely the result of a higher proportion of erythroid 
precursors in the spleen of Zeb2Δ/ΔMx1-Cre mice. Flow cytometry analysis 
demonstrated a noticeable accumulation of proerythroblasts (CD71+Ter119-) 
and erythroblast population (CD71+Ter119+) in both BM and spleen upon 
ablation of Zeb2. As a result of erythroid terminal differentiation defect, 
Zeb2Δ/ΔMx1-Cre mice display anemia and partially compensate this by 
extramedullary erythropoiesis. 
The hemoglobin-oxidizingtoxin PHZ induced hemolytic anemia is mechanically 
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due to increased reactive oxygen species (ROS). ROS production triggers 
cation channels in the erythrocyte membrane. This allows Ca2+ entering the 
cell and translocate the phosphatidylserine (PS) from the inner to the outer of 
the plasma membrane. This translocation can be recognized and further 
engulfed by macrophages (Foller et al., 2008; Lang et al., 2003). Zeb2Δ/ΔMx1-Cre 
mice displayed a pronounced anemia upon PHZ induced oxidative stress 
which implies that Zeb2-deficient mice display impaired (increased) ROS 
levels in response to stress. It has been reported that p53 inhibits stress 
erythropoiesis and the p53-/- mice showed a faster stress response to 
oxidative challenge (Ganguli et al., 2002). The activation of p53 regulates 
cellular ROS generation and mediates apoptosis, and higher ROS levels can 
stabilize p53 and trigger its activation (Liu et al., 2008). Significantly increased 
p53 mRNA level was observed in Zeb2-deficient CD71highTER119+/- population 
compared with controls in the steady-state (data not shown). This might 
account for the increased sensitivity of Zeb2Δ/ΔMx1-Cre mice to stress 
erythropoiesis.  
We also found that upon Zeb2 ablation, several erythropoiesis promoting 
genes, including Gata1, Fli1 and Klf1 were significantly down-regulated in 
Zeb2Δ/ΔMx1-Cre CD71+Ter119+ population, where the maturation block occurs. 
Interestingly, in addition to the critical roles in erythropoiesis, all of those genes 
are essential for megakaryopoiesis as well. Our previous data showed more 
MEP cells but massively diminished thrombocytes in Zeb2 deficient animals. 
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The histological analyzes of the bone marrow cavity and spleens revealed the 
number of megakaryocytes was significantly increased, but the 
megakaryocytes displayed a rather immature morphology with reduced 
amount of cytoplasm and less condensed nucleus in Zeb2Δ/ΔMx1-Cre animals. In 
concordance with this observation ex vivo culture of megakaryocytes using 
CFU-Mk assay revealed a lack of mature, acetylcholinesterase positive 
megakaryocytes in absence of Zeb2, which represents the final maturation 
step of megakaryopoiesis (data from concurrent project, not shown here). 
These data indicate that more megakaryocyte-erythroid progenitors were 
generated in absence of Zeb2, but both erythrocytes and megakaryocytes 
show maturation impairment at the stage of terminal differentiation. Mx1-Cre 
mediated Gata1 deletion in adult hematopoiesis leads to differentiation arrest 
at the proerythroblast stage, severe thrombocytopenia, as well as excessive 
megakaryocytosis in the spleen (Gutierrez et al., 2008), a phenotype similar to 
what we observed in Zeb2Δ/ΔMx1-Cre mice. Klf1 and Fli1 are both Gata1 binding 
partners which play cross-antagonistic roles in the regulation of erythroid 
versus megakaryocytic development (Starck et al., 2003). We have 
investigated the expression level of Klf1 and Fli1 in MEP populations, and both 
genes are up-regulated in Zeb2Δ/ΔMx1-Cre MEPs compared with controls. This 
might explain the excessive erythropoiesis and megakaryopoiesis after Zeb2 
deletion.  
In conclusion, Zeb2 is essential for terminal erythroid differentiation under 
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steady state conditions and maybe dispensable for stress erythropoiesis. The 
maturation arrest upon Zeb2 ablation is mostly due to impaired networks of 
transcription factors, rather than altered cell cycle. 
An important finding of this study is that Zeb2 is not necessary for the 
specification but rather for the differentiation of B-cells. A slightly increased 
number of LMPP was observed in Zeb2Δ/ΔMx1-Cre BM compartment, and this 
may be result from increased LKS population. There were no changes in the 
absolute numbers of CLP cells. However, the transition from Prepro-B to Pro-B 
cells is hindered strikingly in Zeb2 deficient mice. Mechanistically, we 
demonstrated that ablation of Zeb2 leads to inhibited IL-7R expression and 
impaired IL-7 receptor signaling cannot be effectively activated in prepro-B cell 
subset. It is well known that IL-7R signaling is indispensable in orchestrating B 
lymphopoiesis (Clark et al., 2014). A recent study has shown that 
gain-of-function Zeb2 leads to constitutive activation of IL-7/STAT5 signaling 
via direct binding of Zeb2 to the IL-7R promoter element (Goossens et al., 
2015). This finding strongly supports our current findings, as we see in 
absence of Zeb2 the opposite effect on IL-7 signaling to the overexpression of 
Zeb2. In IL-7 or IL-7R-deficient mice, Ebf1 and Pax5 are absent, while E2A is 
normally expressed (Dias et al., 2005; Kikuchi et al., 2005). Consistently, 
expression of Pax5 was almost depleted in Zeb2-deficient Prepro-B population 
and accompanied with mild down-regulated Ebf1. However, in our study E2A 
expression was controversially increased in this cells. This indicates that there 
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might be some other mechanisms responsible for its over-expression. Inhibitor 
of DNA binding 2 and 3 (ID2 and ID3) function to repress E2A and play 
negative role in B-lineage specification. Enforced expression of Ebf1 or E2A in 
IL-7R-/- Prepro-B cells leads to dramatic reduction and induction of both ID2 
and ID3 respectively (Thal et al., 2009). High levels of ID2 were shown in 
Zeb2-deficient Prepro-B population and may be due to inhibited IL-7R and E2A. 
In turn, up-regulated ID2 can inhibit activities of E2A proteins 
posttranslationally and further results in insufficient activation of E2A to rescue 
expression of target genes. Interestingly, ID3 was potently down-regulated and 
might promote B-lymphopoiesis in Zeb2Δ/ΔMx1-Cre Prepro-B cells. However, it 
has been shown before that loss of ID3 in IL-7R-/- mice was not sufficient to 
rescue impaired B-cell development (Thal et al., 2009). This suggest that Zeb2 
is necessary for the transcriptional regulatory network of B-lymphocyte 
differentiation. However, no direct evidence can show the link of Zeb2 to other 
transcription factors, including Gata-3, PU.1 and Runx-1. 
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4.2 Role of Zeb2 in epigenetic regulation  
Zeb2 has been reported to be a transcriptional repressor by interacting with 
multiple subunits of nucleosome remodeling and histone deacetylation (NuRD) 
complex (Verstappen et al., 2008). Our qRT-PCR analysis revealed that in 
addition to NuRD complex, genes associated with polycomb repressive 
complexes 2 (PRC2) (Ezh2 and Suz12), DNA methylation (Dnmt1, 3a and 3b) 
and tet methylcytosine dioxgenases (Tet1, 2, 3) displayed altered expression 
levels in Zeb2-deficient Prepro-B cells as well. A set of important H3 
modifications was dysregulated upon Zeb2 deletion, including H3K4me1, 
H3K4me3 and H3K27me3, which are able to regulate specific B-cell fate 
transcriptomes directly or interplay with transcription factors to establish 
correct genomic landscape of B-lymphopoiesis. These findings implicate the 
important role of Zeb2 in epigenetic regulation of B-cells.  
In recent years, investigators put much effort to clarify the epigenetic 
machinery involved in B-cell development and reprogramming. PU.1 is 
required for lymphoid commitment, and mice lacing PU.1 fail to generate B, T, 
NK and myelomonocytic cells (McKercher et al., 1996; Scott et al., 1994). PU.1 
was reported to promote IL-7R transcription by binding to its Ets sites of the 
promoter (DeKoter et al., 2007). The activated PU.1 in Zeb2-deletion Prepro-B 
cells may be due to the genetic compensation induced by insufficient IL-7R 
expression. A genome-wide study revealed that collaborative interactions 
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between PU.1 and small sets of lineage type specific transcription factors lead 
to nucleosome remodeling and the deposition of H3K4me1, result in activation 
of cistromes of lineage-restricted factors (Heinz et al., 2010).  
A hall mark of B cell lymphopoiesis is the B cell receptor (BCR) 
immunoglobulin rearrangement that consists of heavy chain (Igμ) and light 
chain (Igκ and Igλ). The correct expression of BCR subunits mb-1, which 
encodes the Igα component of Pre-BCR as well, VpreB and λ5, and initiation 
of D-J rearrangements lead to B cell development. The promoter of mb-1 is 
hypermethylated at CpG dinucleotides in HSCs and progressively 
demethylated during B cell development. Synergistic effects of EBF with 
Runx-1 and its partner CBFβ, as well as E2A, results in modified epigenetic 
events of mb-1 promoter, including chromatin structure modulation and CpG 
demethylation and further cause mb-1 activation by Pax5. (Maier et al., 2004). 
Knock-down of Mi-2β, the Mi-2/NuRD complex subunit, in cultured B cells 
results in the demethylation of the mb-1 promoter that indicated restrained 
function of Mi-2/NuRD for EBF and Pax5 induced mb-1 reprogramming (Gao 
et al., 2009). In addition, Mi-2/NuRD complex interacts with Ikaros and Blimp-1 
in B cell development (Dege and Hagman, 2014). A genome-wide analysis has 
been performed to explore the DNA-binding of E2A, EBF1 and Foxo1 by 
Chip-seq. During the transition from Prepro-B to Pro-B cell stage, E2A 
occupied genes were mostly with cistromes were monomethylated at H3K4 
(H3K4me1), characterized as enhancer elements (Lin et al., 2010). In Pro-B 
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cells, gain- and loss- of Ebf1 studies demonstrated that H3K4me3 and H3 
acetylation marks were enriched while repressive H3K27me3 were hampered 
in activated genes (Treiber et al., 2010). The abnormal levels of H3 
modifications in Zeb2-deficiency Prepro-B cells, as shown in our current study, 
might cause broad chromatin changes of B-cell specifying genes, due to 
uncontrolled transcription network during B cell development.  
Interestingly, two members of the PRC2 complex, Eed and Ezh2 and all three 
Dnmts showed significantly increased expression levels in HSC enriched LKS 
population. Aberrant epigenetic regulators are associated with perturbed stem 
cell function (Cullen et al., 2014). Overexpression of Ezh2 is associated with a 
variety of human cancers, including breast and prostate carcinoma (Simon and 
Lange, 2008). In hematopoietic system, gain-of-function mutation of Ezh2 
Y641 results in B-cell lymphomas through selectively increased H3K27me3 
(Sneeringer et al., 2010; Yap et al., 2011). A recent study points to a pivotal 
role of Ezh2 in myeloproliferative diseases. Conditional Ezh2 knock-in mice 
develop MPN features, like excessive myelopoiesis, leukocytosis and 
splenomegaly (Herrera-Merchan et al., 2012), similar to what we observed in 
Zeb2Δ/ΔMx1-Cre mice. As a homolog of Ezh2, Ezh1 could build an alternative 
PRC2 complex with Suz12 and Eed when Ezh2 is insufficient, that could 
explain the limited effects on HSC maintenance upon Ezh2 deletion alone, 
while ablation of the core subunit Eed is likely abolishes complete canonical 
PRC2 function (Xie et al., 2014). Although PRC2 was recognized as a 
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transcriptional repressor via tri-methylation of H3K27, some studies indicated 
that Ezh1 and Ezh2 could function in a histone methyltransferase independent 
way (Mousavi et al., 2012; Xu et al., 2012). However, very little stem cell 
number impedes further mechanistical investigation.  
Numerous studies have pointed out that histone modifications result in and are 
influenced by DNA methylation (Cedar and Bergman, 2009). Fortunately, the 
rapid development of sequencing methods is helping to draw a picture of 
genome-wide methylation profiles from control and Zeb2-deficient HSCs. 
Herein we use reduced representation bisulfite sequencing (RRBS) which 
enables to quantify global DNA methylation in as little as 20ng of DNA. The 
analysis revealed that 72% of all differently methylated CpG sites showed 
higher methylation level in Zeb2-KO HSC. That might be due to the 
up-regulation of both maintenance methyltransferase Dnmt1 and the de novo 
methyltransferases Dnmt3a and Dnmt3b in LKS cells lacking Zeb2. 
Interestingly, 70% of those hyper-methylated CpG sites are located in the gene 
bodies (exons and introns). DNA methylation in promoter regions is relatively 
well characterized as a repressive epigenetic mark. However, the relationship 
between DNA methylation of gene bodies and gene transcription is still unclear. 
However, some studies have shown that methylation in the gene body 
stimulates transcription elongation and splicing, and is positively correlated 
with gene expression (Jones, 2012). Here we show a set of HSC fingerprint 
genes, including Pbx1, Prdm16 and Runx3, harboring differentially methylated 
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CpG sites with higher expression levels in Zeb-KO HSCs. These findings could 
be result from hyper-methylated bodies of those genes. A more recent study 
has explored that 5-Aza-2′-deoxycytidine, the DNA methylation inhibitor, 
down-regulates genes through triggering gene bodies’ demethylation. This 
suggests that high levels of gene body methylation in some overexpressed 
oncogenes could be the potential therapeutic target by methylation inhibitors in 
various cancer (Yang et al., 2014).  
All three DNA methyltransferases are essential for hematopoietic maintenance 
and development. Two studies investigated the impact of Dnmt1 in 
hematopoiesis and were published almost at the same time. Induced loss of 
Dnmt1 in adult hematopoietic cells resulted in rapid mice death due to 
profound anemia and cytopenia caused by absence of HSCs and progenitors, 
and depletion of all hematopoietic lineage cells. Dnmt1−/chip mice, which 
express low Dnmt1 levels, further help to reveal that distinct threshold levels of 
methylation are required for commitment to myeloerythroid and lymphoid 
lineages (Broske et al., 2009b). Another group showed much milder phenotype 
upon ablation of Dnmt1, this may due to insufficient amount of poly (I:C) used 
in this study and thus no efficient deletion of the floxed allele (Trowbridge et al., 
2009). Dnmt3a and Dnmt3b were considered to be important for self-renewal 
of HSCs but not for their differentiation (Tadokoro et al., 2007). A later in vivo 
study showed that Dnmt3a deficiency impairs HSC differentiation over serial 
transplantation while HSC numbers were accumulated. Deletion of Dnmt3a 
99 
 
alters DNA methylation status and selectively increases the expression of HSC 
multipotency genes while downregulate differentiation factors, including 
increased Runx1, Gata3, Nr4a2 and decreased Pu.1, E2A, whose expression 
also changed in Zeb2Δ/ΔMx1-Cre HSCs in our current study (Challen et al., 2012). 
However, the understanding of the mechanism, in which Zeb2 orchestrates 
epigenetic changes remains to be defined in further studies.  
Moreover, all three Dnmts were reported to be substantially overexpressed in 
acute myelogenous leukemia (AML) and chronic myelogenous leukemia (CML) 
(Mizuno et al., 2001). Dnmt3a mutations, including missense, nonsense, 
frame-shift and splice-site mutations have been reported highly recurrent in de 
novo AML patients (22.1%) (Hou et al., 2012; Ley et al., 2010). Moreover, both 
Dnmt3a and Dnmt3b are downregulated in CLL samples. Mice lacking Dnmt3a 
alone or simultaneously with Dnmt3b can develop chronic lymphoid leukemia 
(CLL) rather than AML (Peters et al., 2014). These findings suggested that not 
all of the Dnmt3a mutations in AML completely or partially lose the 
methyltransferase activity, some may result in gain of function as well, and 
lymphocytes might be more sensitive to the expression level of Dnmt3a and 
Dnmt3b. Dnmt1 is highly expressed in leukemia stem cells (LSCs), its 
conditional deletion is able to block transformation and development of 
MLL-AF9-induced leukemia. Haploinsufficiency of Dnmt1 is also sufficient to 
delay leukemic progression (Trowbridge et al., 2012). This indicates that 
Dnmt1 and Dnmt3a/3b might play different roles during leukemogenesis. In 
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this study, we have not observed any bone marrow malignancies in 
Zeb2-deficient mice, in which all three Dnmts were overexpressed in LKS 
population. That could be due to the substraction effect of three Dnmts, or 
additional mutations are likely to be needed, like Flt3 and Npm1. 
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4.3. Role of Zeb2 in cytokine signaling 
Hematopoiesis is tightly regulated by a variety of external stimulating factors 
(e.g cytokines), of which all can transmit signals and activate different signaling 
pathways via their cognate receptors. Ligand binding induces receptor 
dimerization and can rapidly result in the recruitment and phosphorylation of 
downstream kinases like JAKs, which subsequently phosphorylate STATs. The 
activated and dimerized STATs translocate to the nucleus and activate or 
repress target genes. Similarly, AKT and ERK signaling pathways can be 
activated as well (Baker et al., 2007).  
In this study, we observed accelerated activation of the JAK/STAT pathway 
upon G-CSF stimulation, but attenuated activation of the same pathway in the 
presence of IL-3 and IL-6 in Zeb2Δ/ΔMx1-Cre mice compared with controls. 
However, we did not detect altered abundance those cytokine levels in the 
serum of Zeb2Δ/ΔMx1-Cre mice (data not shown). It is known that a particular 
cytokine is not lineage restricted and able to function on different cells, while 
several different cytokines can play similar or overlapping roles in the same 
cell type (Rane and Reddy, 2002). IL-6 signaling is broadly required for 
monocytes, megakaryocytes, hepatocytes and adipocytes, and its 
physiological role could be compensated by leukemia inhibitory factor (LIF) 
and ciliary neurotrophic factor (CNTF) since they shared the same signal 
transducer gp130 (Kishimoto, 1989; Yoshida et al., 1996). IL-6 contributes to 
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the survival and self-renewal of HSCs and early progenitors. Despite the fact 
that IL-6-/- mice can develop normally and grow into healthy adults IL-6 
deficiency leads to abnormal differentiation and commitment of 
granulocytic-monocytic, megakaryocytic and erythroid lineages upon serial 
transplantation (Bernad et al., 1994). This indicated that reduced expression of 
the IL-6Rα in Zeb2-deleted progenitor and myeloid cells compared with control 
is not sufficient to maintain normal differentiation leading to the sever 
differentiation impairment of different lineages in Zeb2-deficient mice. In vitro 
and in vivo studies highlight the critical trombopoietic role of IL-6 in 
megakaryocyte terminal differentiation and maturation (Clarke et al., 1996; 
Ishibashi et al., 1989; Kimura et al., 1990; Stahl et al., 1991). It has been 
shown that IL-6 is able to augment the size and increase the DNA content of 
megakaryocytes, but has no effect on cell cycle. Combining treatment with IL-3 
and IL-6 can considerably increase the megakaryocytic colony formation 
compared with IL-6 alone, suggesting that synergistic effect of IL-3 and IL-6 is 
important for megakaryopoiesis (Kimura et al., 1990). The simultaneous 
attenuated STATs activation response to IL-3 and IL-6 upon Zeb2 deletion 
might account for the severe thrombocytopenia in Zeb2-KO mice.  
It is known that IL-3 stimulates a wide spectrum of hematopoietic progenitors 
and committed lineages, including myeloid cells, megakaryocytes, 
lymphocytes, erythroid cells, and mast cells (Reddy et al., 2000). IL-3 has 
been described as a necessary stimulus in culture medium for proliferation and 
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maturation of HSCs in vitro (Mangi and Newland, 1999). The presence of IL-3 
induces the dimerization of the unique α and the common β chain of the IL-3 
receptor and trigger multiple intracellular signaling transduction cascades. IL-5 
and GM-CSF share the common β (βc) signal transducing subunit as well. We 
analyzed the expression level of IL-3Rα in myeloid cells and progenitors, but 
did not find significant changes. It has been reported that βc does not bind IL-3 
by itself, but associates with IL-3Rα and forms high affinity receptors (Nicola et 
al., 1996). So it is necessary to compare the βc expression in Zeb2-deficient 
and control cells. Moreover, similar to IL-6, either IL-3 or βc–deficient mice 
exhibit no obvious hematopoietic abnormalities, suggesting the compensation 
effect in hematopoiesis by other cytokines (Nicola et al., 1996).  
G-CSF is widely used to induce the mobilization of HSCs from the bone 
marrow to the bloodstream for transplantation (To et al., 1997). In the steady 
state, G-CSF is known to be the major cytokine producing neutrophilic 
granulocytes (Panopoulos and Watowich, 2008). Recombinant G-CSF is 
clinically used for treatment of neutropenia resulting from chemotherapy in 
cancer patients (Morstyn et al., 1988). In hematopoietic system, the G-CSF 
receptor (G-CSFR) is necessary for signal transduction. Its expression has 
been detected in myeloid lineage and correlates with G-CSF sensitivity 
(Panopoulos and Watowich, 2008). Here we detected higher G-CSFR 
expression in Zeb2Δ/ΔMx1-Cre myeloid cells. It has been reported that deletion of 
either G-CSF or G-CSFR result in severe neutropenia phenotype in mice, but 
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a residual level of neutrophil could still be detected (Lieschke et al., 1994; Liu 
et al., 1996). This suggested that in addition to G-CSF/G-CSFR signaling 
pathway, other mechanisms could support granulopoiesis in vivo as well. 
However, when comparing the members of the JAK family that needed for 
G-CSF and IL-3 signaling, we found that G-CSF induces the activation of 
STATs via tyrosine phosphorylation of JAK1 and JAK2, while the activation of 
JAK1 by IL-3 is very limited (Kouro et al., 1996; Tian et al., 1996). It has been 
shown that in the absence of JAK1, G-CSF failed to activate STATs, indication 
that JAK1 is more critical for G-CSF-induced STAT activation (Shimoda et al., 
1997). Interestingly, several CpG sites in exon of Jak1 gene are 
hyper-methylated in Zeb2-KO HSCs, suggesting an increased Jak1 expession 
level. This might account for the more enhanced STATs activation in 
Zeb2Δ/ΔMx1-Cre cells in the presence of G-CSF.  
Our result indicated that increased proportion of granulocytes and progressive 
myeloproliferative disorders in Zeb2-deficiency mice may be due to abnormal 
STATs activation in the presence of G-CSF. In contrast, cells lacking Zeb2 are 
not able to respond to IL-3 and IL-6 stimulation, partly due to reduced receptor 
expression, which might be in part attributing to impaired differentiation of 
multiple hematopoietic lineages.  
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5. Summary 
The differentiation of hematopoietic stem cells (HSC) into specialized blood 
cells is tightly controlled by a complex network of transcription factors (TF). 
The zinc finger E-Box binding TF Zeb2 is known to govern the epithelial to 
mesenchymal transition (EMT) during embryonic development and tumor 
progression and metastasis in an adult organism. Our previous work showed 
that deletion of Zeb2 within hematopoietic compartment resulted in early 
embryonic lethality due to differentiation and migration defects. In order to 
identify the role of Zeb2 in adult hematopoiesis, the Mx1-Cre based inducible 
Zeb2 knockout model was used. We found drastic reduction of B-lymphocytes, 
monocytes, platelets and erythrocytes in peripheral blood while accumulation 
of hematopoietic stem and progenitor cells in the bone marrow after Zeb2 
deletion.  
In this study, we firstly demonstrated that impaired terminal differentiation of 
the erythroid lineage takes place at the transition of CD71highTER119+ to 
CD71medTER119+ population upon Zeb2 ablation. This may be caused by the 
dysregulation of several transcription regulators, including Klf1 and Fli1 and 
Gata1. In addition, the most prominent differentiation block was observed 
within B lymphopoiesis at the Prepro-B to Pro-B cell transition. The early B-cell 
receptor IL-7R as well as fingerprint transcription factors such as Runx1, E2A, 
EBF1 and Pax5 were markedly changed in Zeb2Δ/ΔMx1-Cre Prepro-B cells. 
106 
 
Moreover, the expression level of DNA methylation related genes and histone 
modifications were significantly changed in Zeb-deficient early B-cells, 
suggesting the B-cell differentiation block due to altered epigenetic regulation.  
A set of higher or lower methylated key HSC genes were discovered by 
reduced representation bisulfite sequencing (RRBS) analysis between Zeb2 
WT and Zeb2Δ/ΔMx1-Cre HSCs. Gene ontology (GO) enrichment analysis 
highlights altered protein kinases (including phosphorylation, Serine/threonine 
protein kinase, tyrosine protein kinase) after Zeb2 deletion. This was further 
confirmed by abnormal JAK/STAT activity in Zeb2Δ/ΔMx1-Cre cells.  
In summary, Zeb2 is essential for multilineage differentiation at different stages 
of hematopoiesis. Ablation of Zeb2 in adult hematopoiesis results in defective 
epigenetic regulation, a causative event in impaired transcriptional network 
and JAK/STAT activation that account for multilineage defects.   
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